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The small intestine (SI) is the main site for food absorption and glutamine utilization hence 
critical in metabolic disorders that involve energy balance such as diabetes and obesity. This 
study aims to assess the effects of a known hypoglycaemic compound, oleanolic acid (OA), on 
some enzymes of glutamine metabolism as well as morphological changes in the SI of diabetic 
rats. Diabetes was induced in male Sprague-Dawley rats by intraperitoneal injection of 60 and 40 
mg/kg body weight streptozotocin for type 1 diabetes (T1D) and T2D respectively. One week 
later, different groups of the diabetic rats were treated with OA, insulin or OA + insulin in the 
T1D study and OA or metformin for T2D. Untreated diabetic groups served as controls and non-
diabetic rats were grouped and treated similarly. After 2 weeks of treatment, all the animals were 
euthanized and the SI was differently processed for histological and enzymatic studies. The 
results in both studies indicate significant (p<0.05) increase in the size of the SI and villi in the 
diabetic compared to the non-diabetic groups and these were not ameliorated by all treatments. 
The results suggest that treatment with OA increases villi size independent of diabetes. On the 
other hand, the activity of phosphate dependent glutaminase (PDG) was slightly decreased only 
in T1D and this was not reversed by treatments. Expression of PDG detected by dot blots was 
not different in all groups. The activities of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and glutamate dehydrogenase (GDH) were significantly (p<0.05) 
elevated in diabetic control groups compared to normal controls and all treatments decreased  
ALT and AST activities while only insulin decreased  GDH activity. Furthermore, hexokinase 
activity was elevated by diabetes and OA induces further increase. It is concluded that in the 
early stages of diabetes, OA treatment does not adversely affect PDG activity or expression in 
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Introduction and Literature Review 
1.0 Diabetes mellitus (DM) 
Diabetes mellitus is a term used to describe a group of metabolic disorders resulting from defects 
in either secretion or organ response to insulin and sometimes both, with a resulting 
characteristic hyperglycaemia. When left unmanaged, the chronic high blood glucose level leads 
to long-term pathologies of various organs especially the eyes, kidneys, central nervous system, 
heart and vascular system (ADA, 2013). The prevalence of the disease cuts across all age groups, 
sex and populations, and the number of reported cases is increasing due to the global rise in 
obesity, population growth, ageing and age-specific prevalence (Danaei et al., 2011). People 
with diabetes are at increased risk of developing cardiovascular, peripheral vascular and 
cerebrovascular diseases (Stratton et al., 2000) and have higher susceptibility to communicable 
diseases such as tuberculosis (Jeon and Murray, 2008). The strategic management of the 
condition is aimed at controlling the elevated glucose level and the resulting complications, 
through behavioural and therapeutic interventions (Stumvoll et al., 2005). 
1.1 Epidemiology and economic burden of diabetes 
The current prevalence of diabetes is already 8.3 %  corresponding to 382 million people living 
with diabetes globally and this number is estimated to rise to 592 million by the year 2035 
(Guariguata et al., 2014b). This is a result of both change in the trend of diagnosis and increase 
in the incidence of the disease (Danaei et al., 2011). Regionally, Western Pacific has the largest 
number of people living with diabetes, corresponding to 132 million people while Middle 
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East/North Africa has the highest prevalence with 10.9 %. Africa has the lowest of both where 
15 million people live with diabetes equivalent to 4.5 % prevalence (Whiting et al., 2011).  
However, Africa where countries are low to middle income bears the highest mortality burden. 
Africa alongside other low and middle income countries in other regions account for as high as 
80 % of the deaths caused by diabetes!. Worldwide, diabetes resulted in 4.8 million deaths in 
2012 (Whiting et al., 2011) and it is projected to be the 7
th
 leading cause of all global deaths by 
2030 (Mathers and Loncar, 2006).  Diabetes is also associated with a huge economic burden. In 
2011, annual cost of diabetic care globally was 471 billion US dollars (Whiting et al., 2011) 
which was 19 % higher than was projected for 2025 (IDF, 2003). About 90 % of these costs are 
spent in the economically richest countries while the low and middle-income countries accounted 
for only < 10 %. Moreover, these costs also represent about 13 % of the National health care 
budget expenditure on diabetes in 80 % of the countries (Zhang et al., 2010). South Africa with a 
prevalence of 7.04 % corresponding to close to 2 million adults living with diabetes spent 
approximately 1.4 billion dollars on diabetes in 2011 (Whiting et al., 2011).  
1.2 Classification of diabetes 
The basic classification of diabetes generally takes into account the differences in the etiology 
and/or onset of the disease.  In this context diabetes mellitus is commonly classified into three 
types: Type I and II diabetes mellitus and gestational diabetes. Each of these types of diabetes 
can be diagnosed by measuring the fasting plasma glucose (FPG), random plasma glucose 
(RPG), oral glucose tolerance test (OGTT) or glycated haemoglobin (A1C) depending on the 
severity of the condition. An FPG of ≥ 126 mg/dL (7 mmol/L) or an RPG ≥ 200 mg/dl (11.1 
mmol/L) is enough to diagnose an individual with classic symptoms of hyperglycaemia. 
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However, for an asymptomatic individual, at least one other FPG or RPG or alternatively an oral 
glucose tolerance test (OGTT) is needed to confirm diabetes (Albert and Zimmet, 1998). On the 
other hand an A1C value ≥ 6.5 % reflects long term (usually 2-3 month) diabetes (ADA, 2013). 
 
 Figure 1.1: Global Estimate of the number of people with diabetes in 2013 (20-79 years) 
(Adopted from IDF 2013) 
1.2.1 Type 1 diabetes (T1D) 
Type 1 diabetes or Insulin Dependent Diabetes Mellitus (IDDM) or juvenile onset diabetes 
affects 5-10 % of people living with diabetes and mostly manifests in childhood (Guariguata et 
al., 2014b). This type of diabetes is a result of an autoimmune destruction of pancreatic β-cells 
resulting in defects of insulin secretion (Tuomilehto, 2013). Hence type 1 diabetics inevitably 
rely on exogenous insulin for survival (Atkinson and Eisenbarth, 2001). Normally, the immune 
system differentiates between self and non-self cells in its defense action. However, in type 1 
diabetes, genetic defects coupled to environmental factors lead to the self-destruction of β-cells 
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by immune response which is eventually diagnosed as T1D (Daneman, 2006). This process can 
be detected by markers, among which are islet cell autoantibodies and autoantibodies to the 
insulin hormone (ADA, 2013). In  humans the genes  strongly associated with T1D include those 
for human leukocytes antigen (HLA) and  insulin  among others (Acharjee et al., 2013). On the 
other hand, the contribution of environmental factors to the development of T1D is still poorly 
understood. However, geographical location, exposure to certain substances found in diets and 
high glycaemic index diets seem to play crucial roles in the development of T1D (Acharjee et al., 
2013).  Moreover, a nonstructural protein of coxsackievirus b4 is shown to trigger cytokines 
release from T helper cells which are associated with development of T1D (Varela-Calvino et 
al., 2000), suggesting a connection between parasitic, viral and bacterial infections with 
increased risk of the disease (Herold et al., 2013). 
1.2.2 Type 2 diabetes (T2D) 
Also known as Non-Insulin Dependent Diabetes Mellitus (NIDDM) is the most common type of 
diabetes comprising of approximately 90 % of all people with diabetes (Guariguata et al., 
2014b). Type 2 diabetes is characterized by both diminished organ sensitivity to insulin (insulin 
resistance) and the islet’s β-cells inability to produce more compensatory insulin (Henriksen et 
al., 2011).  
The etiology of insulin resistance is complex, involving genetic predisposition, obesity, 
sedentary life style, pregnancy and hormone excess (Evans et al., 2002). For instance, genetic 
predisposition is reported to increase the risk for T2D by 2.4 fold and the chances of developing 
T2D increases if one or both parents had the disease. Moreover, 15-20 % of the closest relatives 
of a diabetic individual eventually develop a form of impaired glucose tolerance (IGT) (Stumvoll 
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et al., 2005). Also, the incidence of T2D strongly correlates with that of obesity (Figure 1.2)  and 
sometimes the term ―diabesity‖ is used to describe the relationship between the two conditions 
(Castagneto and Mingrone, 2012). Excess visceral and subcutaneous fat which characterizes 
obesity leads to increased circulating unesterified fatty acids that causes poor response to insulin 
especially in skeletal muscle and excess hepatic glucose production (Gastaldelli, 2011). This 
initial defect in insulin response by the skeletal muscle is critical in the development of early 
prediabetic impaired glucose tolerance which culminates in T2D (Leahy, 2005). Non-obese Type 
2 diabetic patients on the other hand may begin with a deficiency in early insulin secretion after 
meal leading to abnormal level of free fatty acids and glucagon responses which further develops 
to diabetes (Bruce et al., 1988).  
Elevated blood glucose level associated with T2D (as well as other types) leads to oxidative 
stress (OS), protein glycation and autoxidation of glucose. Furthermore, oxidative stress is 
particularly important in the etiology of insulin resistance (Evans et al., 2002). Causatively, OS 
has been shown to be partly a result of increased mitochondrial hydrogen peroxide production 
induced by elevated free fatty acids and NADPH oxidase activation (Henriksen et al., 2011). 
This early consequences of hyperglycaemia result in progressive defects of β-cell function 
leading to the characteristic poor insulin secretion observed in T2D (Porte and Kahn, 2001). 
1.2.3 Gestational diabetes mellitus (GDM)  
Gestational diabetes mellitus refers to any degree of glucose intolerance first recognized during 
pregnancy. The condition is continually becoming an important global issue with about 50 % of 
women with early GDM  going on to develop type 2 diabetes within 5-10 years of giving birth. 
Moreover, about 21.4 million GDM cases out of an estimate 127.1 million live births in 2013 
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were reported (Guariguata et al., 2014a). Gestational diabetes results in pregnancy complications 
(ADA, 2013) and infants of GDM patients tend to be more prone to overweight or obesity 
(Guariguata et al., 2014a). 
 
Figure 1.2: Relationship between obesity and insulin resistance (adopted from Gastaldelli, 
2011).  
Key: FFA = free fatty acids, VLDL = very low density lipoprotein, GLP-1 
= glucagon like peptide 1, GNG = gluconeogenesis, ↑ = increase 
1.3 Glucose homeostasis 
Homeostasis is the general term used to refer to the body’s internal mechanism for maintaining 
viable environment for proper well-being. This involves maintaining optimum range of factors 
such as the internal temperature, pH, proteins, oxygen, mineral elements and blood glucose 
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concentration (Schulkin, 2003). Maintaining an optimum level of plasma glucose is a complex 
mechanism that involves crosslink among different metabolic pathways of glucose production 
vis-à-vis consumption in various organs. This homeostatic strategy is of particular importance 
for the brain, red blood cells and some tissues of the eye that rely solely on glucose as an energy 
source for normal metabolic functions (El Bacha et al., 2010). Consequently, the plasma 
concentration of glucose in humans is remarkably maintained at 4.5-5.2 mmol/L and rarely falls 
below 4 mmol/L or rises above 7 mmol/L. The fall of glucose below 4 mmol/L or 
hypoglycaemia, leads to confusion, convulsion, loss of consciousness and eventually death. 
Similarly, acute/chronic elevation of plasma glucose which is the main characteristic of diabetes 
mellitus is equally devastating (Marshall and Bangert, 2008). 
Plasma glucose is derived from the diet and absorbed into the blood stream via the gut or 
produced in tissues. Diet derived glucose may amount to 3000 mmol (540 g) in a 24 hr period. 
This large amount of glucose is taken up for immediate metabolism by tissues such as the central 
nervous system (CNS) (which requires about 30 mmol/hr supply of glucose) and skeletal muscle 
(Berg et al., 2002). Some tissues such as the liver and skeletal muscle further deposit excess 
glucose as glycogen in the process of glycogenesis and once the glycogen pool is filled, glucose 
may then be converted into fats in the liver and adipose tissues (Marshall and Bangert, 2008).  
In the post-absorptive state, stored glycogen is mobilized via glycogenolysis for internal energy 
demands and that in the liver for replenishing the plasma pool. The ability of the liver to 
contribute to plasma glucose is a result of the presence of the enzyme, glucose-6-phosphatase, 
that catalyzes the final step in the production of free glucose from glucose-6-phosphate (Barzilai 
and Rossetti, 1993). After the exhaustion of the glycogen pool, for example under prolonged 
starvation or diabetes, other metabolites such as lactate and amino acids provide carbon skeleton 
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for glucose production via gluconeogenesis. Once again, in these states the liver alongside the 
kidney (under very long starvation) and more recently the small intestine are the known 
gluconeogenic organs that contribute to plasma glucose concentration (Barzilai and Rossetti, 
1993; Mithieux et al., 2004). Apart from their function in glucose production, the kidneys may 
serve to dispose of high glucose levels in to the urine, a condition known as glucosuria. This is 
one of the earliest important symptoms of individuals with chronic diabetes mellitus (Marshall 
and Bangert, 2008). 
Glucose balance is  under tight regulation  by hormonal and chemical signals (Lam et al., 2009), 
like most homeostatic processes in the body. Among the hormones that are known to have effect 
on glucose homeostasis in normal and diseased individuals are the corticosteroids, leptins and 
most importantly the insulin/glucagon ratio (McKay and Cidlowski, 2003; Morton and Schwartz, 
2011; Steiner et al., 1973). Glucocorticoids (corticosteroids) produced by the adrenal cortex 
affect transcriptional and enzymatic processes involved in gluconeogenesis and glycogenesis 
(McKay and Cidlowski, 2003) while adipose tissue-derived leptin acts via the central nervous 
system to maintain energy balance (Morton and Schwartz, 2011). On the other hand, insulin in 
concert with glucagon also affect multiple signaling pathways important in glucose metabolism 
and balance (Marshall and Bangert, 2008).  Impaired action of one or more of these hormones 
may result in hypoglycaemia, glucose intolerance and diseases associated with poor energy 
balance such as obesity and diabetes mellitus. 
1.3.1    Insulin signaling 
Insulin is an α,β-dimer of 21 and 30 amino acids polypeptides linked by two disulfide linkages 
and synthesized in the β-cells of the pancreatic islets (Brange and Langkjœr, 1993). The 
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secretion of the hormone is triggered by increase in blood glucose level, for example after a 
carbohydrate rich meal. Once released, insulin causes receptor mediated transmembrane 
transport of glucose into cells (Figure 1.3)  of insulin sensitive tissues which include white 
adipose tissue, brown adipose tissue and skeletal muscle (Way et al., 2001). This occurs in 
concert with changes  in glucagon secretion and entails the body’s regulatory mechanism for 
blood glucose balance (Steiner et al., 1973). 
 
Figure 1.3: Insulin signalling cascade (adopted from Abdul-Ghani and DeFronzo 2010) 
Key: IRS-1 = insulin receptor substrate 1, PI-3-kinase = phosphatidyl inositol 3-
kinase, p85 = 85 kDa subunit of PI-3-K, p110 = 110 kDa subunit of PI-3-K, Akt = 
protein kinase B/Akt, NOS = nitric oxide synthase, GLUT 4 = glucose transporter 4. 
Insulin binding to extracellular α-subunit of IRS-1 causes phosphorylation of multiple 
tyrosine residues on transmembrane β-subunit of IRS-1. The phosphorylated tyrosine 
residues mediate an activating association between 85 kDa regulatory subunit and 110 
kDa catalytic subunit of PI-3-K. Activation of PI-3-K in turn leads to activation of Akt 
which initiates the processes involved in the translocation of GLUT 4 containing vesicles 
to the plasma membrane. Finally GLUT 4 acts as the major transporter of glucose from 
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the extracellular to the intracellular compartment of insulin sensitive tissues. Insulin also 
regulates protein, lipid and glycogen synthesis via the activated PI-3-K as well as 
activation of nitric oxide synthase. Nitric oxide synthase generates nitric oxide in the 
endothelium with protective consequences on the endothelial lining (Abdul-Ghani and 
DeFronzo, 2010). 
Insulin possesses positive regulatory effects on the transcription of glycolytic enzymes which 
include glucokinase and phosphofructokinase and negative effect on phosphoenolpyruvate 
carboxykinase which is gluconeogenic. Hence, when any of the many factors that impair insulin 
release or organ response occurs, disturbance in body’s glucose homeostasis results which 
manifests in early impaired glucose tolerance (IGT) and consequently diabetes mellitus (Leahy, 
2005).  
Glucagon unlike insulin is a single polypeptide of 29 amino acids secreted from α-cells of the 
pancreas. The insulin:glucagon ratio determines the anabolic-catabolic setting in an organism. As 
a result, both insulin and glucagon have other regulatory effects on nutrients metabolism apart 
from the maintenance of optimum blood glucose level (Jaspan and Rubenstein, 1977).  
1.4       Pathophysiology of diabetes 
Diabetes is accompanied by increased risk of many microvascular and macrovascular diseases. 
Although the pathogenesis of type 1 and type 2 diabetes are different, the pathophysiology of 
their resulting vascular complications is similar (van Dijk and Berl, 2004). The main cause of 
these complications is the hyperglycaemia associated with both type 1 and type 2 diabetes which 
selectively damages cells found in the endothelium and mesangial cells (Brownlee, 2005). Thus, 




vessels found in organs throughout the body (Dokken, 2008) especially the eyes, kidneys and 
nerves (Brownlee, 2005). This is basically due to the inability of the cells found in these organs 
to reduce the in-flux of elevated blood glucose concentration. Approximately one third to half of 
the people with diabetes are affected with diabetes-induced organ damage as a result of the 
microvascular (retinopathy, neuropathy and nephropathy), and macrovascular (cardiovascular 
disease, cerebrovascular diseases and peripheral vascular diseases) complications. Factors that 
increase the risk of developing diabetes complications include; hyperglycaemia, duration of 
diabetes, age, tobacco use, hypertension and dyslipidemia (Cade, 2008). 
An underlying way through which high blood glucose leads to these pathological changes has 
been identified to be hyperglycaemia-induced increase in reactive oxygen species (ROS). 
Increased ROS such as superoxide leads to inhibition of glyceraldehydes-3-phospahate 
dehydrogenase (GAPDH) by activating poly (ADP-ribose) polymerase (PARP) (Brownlee, 
2005). Accumulation of upstream glycolytic metabolites as the result of GAPDH inhibition 
activates the pathways that are central to the pathology of diabetes. These activations include: 
increase flux in the polyol pathway, increased formation of advanced glycation end products 
(AGEs), induced activation of protein kinase C (PKC) and increased flux into hexosamine 
pathway (Brownlee, 2001). Superoxide can also interact with nitric oxide produced by nitric 
oxide synthase isozymes found in the endothelium. This leads to generation of peroxynitrite, 
which is a strong DNA and protein damaging oxidant, leading to increased cardiovascular 
dysfunction (Pacher and Szabó, 2006). However, hyperglycaemia does not directly lead to 
macrovascular damage observed in diabetes. Rather, the damage was proposed to initiate from a 
different mechanism which in the end leads to activation of the four pathways as for 
microvascular damage. This mechanism is the increased flux of free fatty acids (FFA) from 
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adipocytes to the macrovascular endothelium. Subsequent β-oxidation of the FFA and oxidation 
of the acetyl-coA produced through the process increase intracellular electron donors that in turn 
increase ROS and the eventual macrovascular damage (Brownlee, 2005).  
1.5       Management and treatment of diabetes  
Management of T1D and T2D differ in relation to the different etiologies of the conditions. 
Because T1D involves destruction of β-cells, the patients inevitably rely on exogenous insulin 
for survival. However, combined therapy with other agents that reduce the resulting pathologies, 
such as cardiovascular complications, is often implemented. Insulin treatment of type 1 diabetes 
involves subcutaneous doses of insulin at intervals before and after meal depending on the type 
of the regimen and the age of the individual (Shulman and Daneman, 2010). However, the 
treatment requires the patient and/or his family to master the procedures involved such as the 
insulin injection, glucose monitoring and recommended nutritional plan. Different approaches 
are employed for the delivery of the insulin regimens which may involve combination of basal 
bolus with either daily doses of insulin injections or insulin pumps. This is often tricky and 
sometimes the treatment involves the risk of developing hypoglycaemia even when appropriately 
followed. Fortunately, advances in diabetes care allows for easier hormone delivery and simpler 
glucose monitoring (Atkinson and Eisenbarth, 2001; Van Belle et al., 2011). Moreover, various 
forms of recombinant human insulin with better pharmacokinetics than the conventional insulin 
are now commercially available in some parts of the world (Atkinson and Eisenbarth, 2001). 
On the other hand, different classes of drugs are in use for the management and treatment of 
T2D. The main aim of the therapeutic intervention is to ameliorate glucose tolerance or at least 
prevent the long term effects of hyperglycaemia. As a result, many drugs are targeted to improve 
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the organ sensitivity to insulin because of its central role in the pathogenesis of the disease 
(Stumvoll et al., 2005). Although exogenous insulin cannot be a rationale treatment for type 2 
diabetes, increasing the level of circulating insulin is sometimes one of the strategies in 
improving the efficacy of insulin sensitizers. Hence, low doses of insulin are often used in a 
combination therapy with drugs used to treat T2D such as metformin (Stumvoll et al., 2005). 
Several other classes of drugs have been developed over the years each with a unique mechanism 
of action. However, almost all of these drugs are not without one form of side effect or another 
(Table 1.1). Among these drugs are the thiazolidinediones which improve tissue sensitivity to  
insulin (Stumvoll et al., 2005). The main site of action of these drugs is the adipocytes, where the 
receptor, peroxisome proliferator-activator receptor gamma (PPARγ) is highly expressed. 
Activation of PPARγ modulates free fatty acid metabolism and redistribution as well as 
adipokines secretion. Furthermore, the associated reduction in the circulating tumor necrosis 
factor α and increase in adinopectin cytokines with these drugs improves insulin sensitivity in the 
peripheral tissues (Hauner, 2002). 
Another class of popular antidiabetic drugs are the biguanides of which metformin is currently in 
use (Cheng and Fantus, 2005). Metformin is an effective anti-hyperglycaemic drug that acts 
independent of the pancreas (Stumvoll et al., 2005). Despite the long use of metformin clinically, 
its mechanisms of action are still not fully elucidated. However, decrease intestinal glucose 
absorption, plasma free fatty acids and liver gluconeogenesis, and increase glucose delivery to 
cells are described to be some of the ways through which metformin imposes its observed anti-
hyperglycaemic effects (Grzybowska et al., 2010).   
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Acarbose, an α-glucosidase inhibitor, has also been an effective anti-hyperglycaemic drug. It 
inhibits diasaccharidases found in the proximal intestine which are responsible for the 
breakdown of dietary oligosaccharides and disaccharides.  Therefore, acarbose essentially delays 
the intestinal absorption of carbohydrate and consequently reduces postprandial blood glucose 
levels. The efficacy of this class of drugs is less than that of most oral anti-hyperglycaemic 
agents (OHAs), hence they are mostly used clinically in combination with other OHAs 
(Lebovitz, 1997).   
Some anti-diabetic drugs exert their action by binding directly to receptors found on the 
pancreas. Sulfonylureas basically improve insulin secretion from the β-cells through binding to 
their receptor that is intimately associated with an ATP sensitive potassium channel found on the 
membrane of the cells (Panten et al., 1996). Binding of sulfonylureas to the receptor-channel 
complex causes membrane depolarization of resting β-cells via inhibition of cross-membrane 
efflux of potassium. This depolarization further results in the opening of calcium channels, 
facilitating influx of calcium which causes the exocytosis of insulin from storage vesicles (Cheng 
and Fantus, 2005).  Given that this action is irrespective of the blood glucose levels, it is possible 
to develop hypoglycaemia with the treatment. 
The treatment approach that appears to take into account the blood glucose level involves the 
incretin hormones which are secreted from distal small intestine. Glucagon-like peptide 1(GLP-
1)  possesses a glucose-dependent insulinotrophic effect as well as β-cell trophic and intestinal 
motility inhibitory effects which collectively result in reduced blood glucose levels (Stumvoll et 
al., 2005). However, the circulating hormone is vigorously inactivated by dipeptidyl peptidase-4 
(DPP-4), making it therapeutically impossible to use exogenous GLP-1 like insulin. Thus, GLP-1 
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analogues resistant to DPP-4 and DPP-4 inhibitors are used for the treatment of T2D clinically 
(Namba et al., 2013).   
Recently, surgical procedures have emerged to be the safe and effective treatments for T2D (Sala 
et al., 2012). Originally, bariatric surgery such as gastric banding was used for the treatment of 
obesity. However, it was later experienced that obese patients with T2D recover from diabetes 
after the surgery in parallel with weight loss. This recovery from diabetes was initially solely 
attributed to the weight loss after gastric banding, which is essentially a surgical insertion of a 
plastic band in the stomach to limit food intake (Castagneto and Mingrone, 2012). Subsequently, 
the observation that a robust glycaemic control occurs with more advanced surgical procedures 
such as the gastric bypass suggested other mechanisms independent of weight loss (Cohen et al., 
2011). Gastric bypass involves excluding some length of the small intestine from food transit, 
resulting in lower nutrient absorption among other effects. This raised interest on the importance 
of the small intestine in glucose homeostasis especially during diabetes (Mithieux, 2009). The 
proposed mechanisms for the anti-diabetic effects of bariatric surgeries include; stimulation of 
intestinal gluconeogenesis, increase secretion of insulinotrophic hormones and inhibition of anti-
incretins from the foregut (Sala et al., 2012). 
Other surgeries such as pancreas and islets transplantation have also emerged as surgical cures 
for type 1 diabetes. However, transplantation must be accompanied by immunosuppressive drug 
treatment to prevent rejection and/or recurrent autoimmune destruction of the transplants. 
Moreover, lack of organ donors is another major obstacle to the procedure (Atkinson and 
Eisenbarth, 2001). When successful, pancreas transplant results in exogenous insulin 
independence and improvement of cardiac and cardiovascular risk factors (Coppelli et al., 2003) 
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as well as reduction in proteinuria associated with early diabetic nephropathy (Paleologo et al., 
2004).     
1.5.1   Management of other diabetic complications  
T2D is associated with increased risk of hypertension, cerebrovascular diseases and coronary 
artery diseases. Hence, management of other complications alongside glycaemic control is 
beneficial. Angiotensin converting enzyme (ACE) inhibitors and statins are respectively 
associated with decrease risk of hypertension and dyslipidemia in diabetics. Drugs associated 
with decrease risk of atherosclerosis such as aspirin are also recommended as a secondary 
therapy during diabetes (Stumvoll et al., 2005). Physical therapy may also be used to reduce the 
risk of microvascular and macrovascular diseases through the physical management of obesity, 
pain and poor endurance. In achieving that, monitoring the exercise of diabetic patients is 
especially important (Cade, 2008).  
1.6 The gastrointestinal system (GIS) 
The gastrointestinal system essentially consists of the gastrointestinal tract and the associated 
glands. The gastrointestinal tract is the tube that runs from the oral cavity, through the 
esophagus, stomach, small and large intestine, rectum, and the anus and is further categorized 
into the upper and lower gastrointestinal tract. The upper gastrointestinal tract starts from the oral 
cavity down to the small intestine and performs functions such as the transport of digested food, 
enzymatic secretion, nutrients digestion and absorption, and protection against the external 
environment (Treuting et al., 2012). Digestion of ingested food is initiated by enzymes secreted 
in the mouth and continued by gastric secretions with minimal absorptions taking place (DeSesso 
and Jacobson, 2001). On the other hand, the small intestine is the major site of nutrient digestion  
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Table 1.1: Advantages and disadvantages of various treatment methods for diabetes 
Treatment Advantages Disadvantages Example of drug References 
Exogenous insulin  Rapid action 
 Treatment for type 1 diabetes 
 Risk of hypoglycaemia 
 Very technical 
 invasiveness 
Rapid acting, short acting, pre-
mixed insulin  
Shulman and 
Daneman, 2010 
Thiazolidinediones  Improvement of vascular 
abnormalities 
 Amelioration of dyslipidemia 
 Weight gain 
 Anemia 
 Edema 
 Cognitive heart failure 
Pioglitazone, rosiglitazone Cheng and Fentus, 
2005 
Biguanides  No weight gain 
 Improvement of lipid profile 
 Decrease cardiovascular risks 





(withdrawn from market due to 
toxic effects)  
Stumvoll et al. 
,2005; Cheng and 
Fentus, 2005 
α-glucosidase inhibitors   Good safety profile, 
 No risk of hypoglycaemia 
 Decrease post-prandial plasma 
triacylglyceride levels 
 Flatulence 
 Abdominal discomfort 
 Bloating 
 Diarrhea 
Acarbose, miglitol, voglibose Lebovitz, 1997; 
Cheng and Fentus, 
2005 
Sulfonylureas  Successful glycaemic control 
 Decrease microvascular and 
macrovascular complications 
 Risk of hypoglycaemia 




Stumvoll et al., 
2005 
Incretin based therapy  Glucose dependent action 
 Cardiovascular protective effect 





Surgical procedures  No risks of drug complications 
 Robust results 
 Maximal invasiveness 
 Immune compromise (in case of 
islets transplant) 
Gastric bypass, duodeno-
jejunectomy, pancreas and Islet 
transplants 




and absorption due to its anatomical and physiological adaptations (Reed and Wickham, 
2009).  Although the GIT represents only about 5 % of the total body mass, it accounts for 
approximately 20 % of total oxygen consumption of the body due to the high energy demand 
as the lining GIT is renewed and the high activity of transmembrane transporters (Blachier et 
al., 2009). Consequently, the GIS is paramount in the energy homeostasis in mammals and a 
strong relationship exists between the gastrointestinal motor and sensory functions and 
overall blood glucose control (Rayner et al., 2001). Hence, this link is particularly important 
in disorders that involves energy metabolism such as diabetes mellitus.   
1.6.1  The small intestine (SI)  
The SI deserves particular consideration because of the critical function it performs in blood 
glucose homeostasis. These functions include digestion of food, nutrients absorption, and 
secretion of hormones. In humans, small intestine accounts for about 81 % of the total length 
of the approximately 835 cm intestinal canal.  The SI consists of three subdivisions which are 
the duodenum (25 cm), jejunum (260 cm) and ileum (395 cm). Similarly, in rats the SI runs 
an average length of 125 cm which is 83 % of the total intestinal canal comprising of 9.5-10 
cm duodenum, 90-135 cm jejunum and 2.5-3.5 cm ileum (DeSesso and Jacobson, 2001). 
After the passage of chyme (partially digested food) from the stomach to the duodenum, 
enzymes originating from the stomach, intestine and pancreas as well as bile acids are 
secreted to continue with the digestion in the duodenum (Reed and Wickham, 2009). 
Moreover, absorption of nutrients largely occurs in the duodenum and the proximal jejunum 
which is enhanced by some permanent spiral or circular folds termed the plicae circulares 
found on the intestinal lining or mucosa (Figure 1.4). The surface area of the mucosa is 
further enhanced by the villi (singular: villus) and crypts which are fingerlike projections and 
depressions respectively as well as smaller microvilli. Furthermore, the epithelium of the villi 
and crypts is lined by a continuous sheet of absorptive enterocytes. Additionally, each villus 
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has an artery, a vein and a specialized lymphatic channel that absorbs and transport nutrients 
called the lacteal.  Absorbed carbohydrates (and proteins) or lipids enter the circulation via 
the portal blood or are secreted into lymph as chylomicron particles respectively (Kohan et 
al., 2011). Outside the epithelial mucosa lies a layer of connective tissue consisting of blood 
and lymphatic vessels called the lamina propria. The lamina propria absorb and deliver 
nutrients as well as transport hormones secreted by endocrine cells found on the endothelium 
(Reed and Wickham, 2009). Moreover, goblet cells are found throughout the length of the 
small intestine. These cells synthesize and secret mucins which forms the protective mucous 
membrane of the small intestine (Specian and Oliver, 1991).   
 
Figure 1.4: Internal structure of the small intestine (adopted from OpenStax, 2013) 
1.7 Role of the small intestine in glucose homeostasis 
Although glucose is not the main metabolic fuel for the small intestine, the organ is central to 
glucose homeostasis. Recently, organs other than the liver, muscle and pancreas have been  
receiving more attention in the attempt to elucidate the etiology, pathogenesis and treatments 
of diabetes mellitus (Maggs et al., 2008). The gastrointestinal tract in general is continuously 
viewed as an important component of glucose homeostasis especially in a diabetic state. The 
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―portal glucose signal‖ is a known phenomenon that influences several aspects of glucose 
homeostasis via a neural-mediated mechanism involving hepatoportal vagal and spinal 
afferents (Mithieux, 2010). This alongside other signals prevents endogenous glucose 
production (EGP) in a fed state via the suppression of glucagon and stimulation of insulin 
release. Moreover, the gastrointestinal tract becomes the major source of blood glucose after 
feeding (Aronoff et al., 2004) and this is key to determining postprandial glucose flux into 
the circulation. Interestingly, the rate limiting step of ―gastric emptying‖ is not affected by 
either insulin or glucagon (Maggs et al., 2008).  Rather, the delivery of eaten food from the 
stomach to the duodenum is affected by several other hormones involved in glucose 
regulation, some of which are of intestinal origin. These hormones include amylin from the 
pancreas, and glucose-dependent insulinotrophic peptide (GIP) and glucagon like peptide 1 
(GLP-1) secreted by the L-cells of the small intestine (Aronoff et al., 2004). The intestine 
further regulates energy metabolism by sensing the accumulation of long chain fatty acid 
which is a signal to the gut-brain axis through the nervous system to decrease satiety and 
hepatic glucose production (Breen et al., 2011). 
During a fasting state, the plasma glucose concentration is a function of the rate of 
endogenous glucose production (EGP) by the liver and its uptake by other tissues of the body 
(Maggs et al., 2008). To achieve adequate EGP in this state, the hormone glucagon, released 
from the pancreatic α-cells stimulates hepatic glucose production (HGP), via glycogenolysis 
or gluconeogenesis during a short or long fasting respectively (Aronoff et al., 2004). 
Moreover, there are increasing evidences that, the small intestine expresses glucose-6-
phosphatase, the enzyme necessary for the release of glucose into the circulation (Croset et 
al., 2001), and contributes to blood glucose substantially during long fasting and diabetes 
(Mithieux et al., 2004). Also, the SI has been shown to deposit glycogen synthesized from 
absorbed glucose and this property has been utilized as a target for glucose disposal for 
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conditions such as diabetes (Khathi et al., 2013). As mentioned previously, surgeries that 
target the small intestine have been successful in ameliorating glucose tolerance in diabetes, 
further suggesting a special role of the small intestine in glucose homeostasis (Rubino, 2008). 
When glucose is utilized in the small intestine, the first step of its conversion is catalyzed by 
the enzyme; hexokinase (EC 2.7.1.1). Hexokinase catalyzes the phosphorylation of glucose 
(and other hexoses) using ATP as phosphoryl donor generating glucose-6-phosphate (Figure 
1.5) as product (Wilson, 2003). Four distinct isozymes that play different roles have been 
identified in mammals namely; type I, type II, type III and type IV (also referred to as 
glucose kinase due to its high  Km for glucose). Furthermore, the small intestine has been 
shown to express type I and type II HK as major types as well as type III and IV in lesser 
quantity (Weiser et al., 1971). Hexokinase has been shown to be the rate limiting enzymes for 
glycolysis in the small intestinal mucosa and hence critical in glucose utilization. The activity 
of HK has been shown to be altered under different feeding conditions, aging and metabolic 
disorders (Jones and Mayer, 1973; Srivastava and Hubscher, 1968). Glucose feeding 
increased HK activity while starvation was observed to decrease the activity in both 
mitochondrial and soluble preparations of rat jejunum. Diabetes on the other hand increased 
the activity of soluble form of hexokinase while decreasing the mitochondrial bound HK 
signifying release of mitochondrial bound HK (Anderson and King, 1975).   
1.8      Glutamine metabolism in the SI 
Glutamine is the most abundant plasma amino acid that performs many functions in different 
organs which include acting as: an oxidative fuel for intestine; the major gluconeogenic 
precursor for the liver; substrate for the synthesis of protein, urea, nucleotides and nucleic 
acids;  inter-organ nitrogen transport; precursor for neurotransmitter; and source of ammonia 




Figure 1.5: Phosphorylation of glucose catalyzed by hexokinase as the first step of common 
pathways of glucose metabolism 
Glutamine alongside the ketone bodies has been identified as the major fuel sources for the 
small intestine (Table 1.2). Apart from its function as an energy source, glutamine is 
important physiologically in the prevention of intestinal injury (Chang et al., 2001) and 
general maintenance of gut integrity (Newsholme et al., 2003).  The SI is responsible for the 
removal of almost the entire glutamine produced from other organs, mainly skeletal muscle, 
suggesting a large influx of glutamine (Schrock and Goldstein, 1981). However glutamine 
accounts for approximately 35 % only of the total varbon (IV) oxide (CO2) production by the 
SI under normal metabolic state (Windmueller and Spaeth, 1978). The remainder of the 
glutamine serves as a precursor for lactate and other amino acids such as alanine, citrulline, 
proline and ornithine (Mithieux, 2001).  
A different role of glutamine is activated during fasting and diabetes. In these states, the 
intestinal net glucose release via gluconeogenesis becomes important and glutamine serves as 
the major precursor. In addition, the associated portal release of alanine contributes to hepatic 
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gluconeogenesis, thus intestinal glutamine utilization during fasting and diabetes is critical in 
the overall glucose homeostasis (Mithieux, 2001). 
Table 1.2: Contribution of arterial metabolites to intestinal CO2 production (Windmueller 
and    Spaeth, 1978) 






Unesterified fatty acids 3.4 
Total 100 
 
1.8.1 Phosphate dependent glutaminase (PDG) in the small intestine 
Glutaminase (EC 3.5.1.2) catalyzes the oxidative deamidation of glutamine to yield glutamate 
and ammonia. Two forms of glutaminases with strong similarity in amino acid sequence 
identity are known: the hepatic type which is found only in the liver and the kidney type 
which has wider organ distribution  (McCauley et al., 1999). Apart from the difference in 
organ distribution, another major variation between the hepatic and renal isoforms is their 
pattern of regulation. While the hepatic type is affected by nutritional status such as diabetes, 
high protein diet and fasting, the kidney type appears to be regulated by acid-base status only 
(Watford, 1993). The kidney type glutaminase is also highly active as well as the major 
glutamine metabolizing enzyme in the SI. The enzyme is phosphate dependent and associated 
with the mitochondria of the enterocytes found along both the villus and crypt of duodenum, 
jejunum and ileum. Moreover, the intestinal phosphate dependent glutaminase (PDG) 
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resembles the kidney type 72 kDA glutaminase in terms of expression (Pinkus and 
Windmueller, 1977). However, the intestinal glutaminase unlike the kidney type is not 
activated by acidosis. The SI glutaminase is rather activated by phosphate (Pi), bicarbonate 
and sulphate but inhibited by ammonium ions (Masola and Zvinavashe, 2003). Maximum 
activity of the enzyme was obtained at Pi concentration of 10 mM at pH 9 (Masola and 
Ngubane, 2010). In the same study the stability of mitochondrial membrane has been shown 
to be pivotal for the activity of the enzyme. Furthermore, ADP, AMP and ATP nucleotides 
activate the enzymes with ADP being the highest activator (Masola and Ngubane, 2010). A 
concentration of 100 mM of phosphate is necessary for the dimerization and activation of 
isolated glutaminase. Moreover, glutamate is a feedback inhibitor of the enzyme among other 
inhibitors (McCauley et al., 1999). Other factors that increase the activity of the enzyme 
include weaning (Hahn et al., 1998), lactation (Ardawi, 1987) and presence of 
glucocorticoids (Sarantos et al., 1992). and increased liver cirrhosis (Romero-Gómez et al., 
2004) while sepsis (Ardawi et al., 1990), interleukins and interferon-γ (Austgen et al.1992; 
Sarantos et al., 1994) cause decrease in activity.  Furthermore, starvation (Kong et al., 2000) 
and glucocorticoids (Sarantos et al., 1992) increase the expression of small intestinal 
glutaminase. Intestinal PDG is important because it catalyzes the first reaction that commits 
carbon skeleton of glutamine to energy production, protein synthesis or a more recently 
discovered function of the SI, gluconeogenesis, depending on the metabolic condition (Croset 
et al., 2001). During prolonged diabetes, the activity of PDG in the small intestine is 
increased up to 40 % which makes it crucial in the overall glucose homeostasis during 
diabetes (Mithieux et al., 2004). 
1.8.2 Glutamate dehydrogenase (GDH) in the small intestine 
Glutamate dehydrogenase (GDH) (EC 1.4.1.3) is a mitochondrial matrix enzyme that 







 as a coenzyme (Fang et al., 2002; Smith and Stanley, 2008). In 
mammals, the enzyme consists of six identical subunits of approximately 56 kDa and 550 
amino acids each and is found in various tissues including the liver, brain, pancreatic islet, 
kidney and intestine (Mastorodemos et al., 2005). The regulation of GDH is tight with the 
major activators being ADP and leucine while GTP and ATP being the major inhibitors (Li et 
al., 2012). The direction of either glutamate production or deamination by GDH depends on 
the redox potential of the mitochondria. At high NADH/NAD
+ 
ratio such as at normal fed 
state, reductive transamination of α-KG is favored thereby yielding glutamate as the 
cataplerotic product. Conversely, at low NADH/NAD
+ 
ratio flux in the α-KG direction is 
favored (Frigerio et al., 2008).  
A mutation in GDH gene whereby the GTP binding site is altered leads to hyper-activation of 
the enzyme leading to leucine dependent excessive increase in β-cell insulin release. The 
resulting hyperinsulinism is associated with excess amount of ammonia a condition known as 
hyperinsulinism/hyperammonemia syndrome observed in infants and children with a 
characteristic hypoglycaemia (Fang et al., 2002).  
1.8.3 Alanine aminotransferase and aspartate aminotransferase in the SI 
Alanine aminotransferase (ALT) (EC 2.6.1.2) and aspartate aminotransferase (AST) (EC 
2.6.1.1) play a major role in the interplay between glucose and amino acids metabolism in the 
body (Sookoian and Pirola, 2012). The enzymes have wide tissue distribution and perform 
vital functions in liver, kidney and small intestine where the activities of the enzymes are 
high (Kobayashi et al., 2010). In the intestine, the metabolic fate of glutamine and glutamate 
is not entirely oxidation. Although most of the dietary and endogenous glutamine as well as 
glutamate undergo oxidation to CO2 in the intestine, the remaining are converted to lactate 
and other amino acids and released in to the portal circulation (Burrin and Stoll, 2009). The 
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main route for the conversion of glutamate to α-KG in the enterocytes is through 
transamination reaction because of the low capacity of these cells for glutamate 
dehydrogenase reaction (Blachier et al., 2009). This transamination, catalyzed by either ALT 
or AST occurs in the presence of pyruvate or oxaloacetate, to yield α-KG and alanine or 
aspartate respectively.  
 
Figure 1.6: Metabolic pathways cross links between glutamine and glucose during diabetes 
(adopted from Mithieux, 2001) 
Key: plain lines = routes of glutamine carbons,   broken lines = routes of glucose carbons 
(major routes in bold),   Ala = alanine,   α-KG = α-ketoglutarate,   Glc6P = glucose-6-
phosphate,   Glc6Pase = glucose-6-phophatase,   Gln = glutamine,   Glu = glutamate,   G3P = 
glycerol-3-phosphate,   Lac = lactate,   LDH = lactate dehydrogenase,   ME = malic enzyme,   
OAA = oxaloacetate,   OAADC = oxaloacetate decarboxylase,   PC = pyruvate carboxylase,   
PEP = phosphoenolpyruvate,   PEPCK = phosphoenolpyruvate carboxykinase,   Pi = 




The serum activities of the enzymes are routinely used clinically as markers of liver damage. 
However, abnormal levels of the serum level of the enzymes is also associated with increased 
risk of metabolic syndrome including type 2 diabetes (Sookoian and Pirola, 2012). Moreover, 
decreased serum activity of ALT was observed to correlate with small intestinal ALT 
activities in rats maintained under intermittent feeding. Hence, in addition to liver injury, the 
activities of the enzymes in tissues is altered by hormonal and nutritional modifications 
(Kobayashi et al., 2010). ALT in addition plays a central role in linking glutamine and 
glucose metabolism in the small intestine (Figure 1.6),  hence critical in energy utilization of 
the organ (Mithieux, 2001).  
1.9 Diabetes induced and morphological and metabolic changes in the small intestine 
1.9.1 Morphological changes in the small intestine during diabetes 
Increase in weight of the small intestine resulting from diabetes was recorded as early as 8 
days after induction in rats. This rose up progressively up to 140 days after induction at 
which the wet of the SI may be doubled that of normal rats and this is about four times when 
expressed per body weight. Increase intestinal length (16.6 %) and circumference (3.6 %) 
were also recorded by around 6 weeks after diabetes induction in rats. The increased weight 
was found to be predominantly in the mucosal scraping rather than the underlying tissue 
(Schedl and Wilson, 1971). Moreover, microscopic examination of diabetic SI also showed 
various forms of pathological abnormalities. In a study using diabetic Chinese hamsters, the 
villi were observed to be deformed and longer (10.7 %) with concomitant excessive lesions 
(13-53 %), lymphocytes aggregations (6-40 %) and elevated number of goblet cells (11-33 
%) (Diani et al.,1976). Moreover, diabetes has been found to increase only the number of 
goblet cells but the intracellular mucin content of the SI was decreased. Furthermore, a 
decrease in crypts depth has been noted to occur late in diabetes (Mantle et al., 1989). On the 
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other hand, the underlying muscluris interna, muscularis externa (14-47 %) and Auerchbach 
plexuses (14-47 %) were reduced in diabetic animals compared to normal hamsters (Diani et 
al., 1976). However, contrasting data on the muscular thickness was obtained with 
experimental type 1 diabetic rats. Zhao et al. (2003) reported a marked increase (up to 20 %) 
in all of mucosal, submucosal and total wall thickness from day 7 up to 4 weeks after 
induction of STZ-type 1 model of diabetes. Further findings from the study are that opening 
angle and residual strain which reflect the elastic properties of the SI were lower in the 
duodenum and higher in the jejunum and ileum of diabetic rats compared to non-diabetic rats. 
Subsequent findings by the same research group showed the observation to be true of type 2-
diabetic model Goto-Kakizaki (GK) rats and is positively correlated with the level of blood 
glucose and advanced glycation end products (AGEs) (Zhao et al., 2013). Contrary to these 
findings, similar study on the tension-strain relations found no difference in mucosa, 
submucosa and muscle layer thickness in experimental diabetic rats injected with lower STZ 
(28 mg/kg body weight) dose after 28 days. In agreement however, the study also suggested 
increase in wall stiffness in the jejunum and ileum of the diabetic rats (Jørgensen et al., 
2001). The disparity in the result may be due to the differences in the resulting rise in blood 
glucose levels. The latter study reported just around half the blood glucose level of the 
previous study further suggesting a relationship between the morphomechanical changes to 
blood glucose levels. The authors suggest these observed changes that affect both 
longitudinal and circumferential stiffness of the SI to be in part responsible for the abdominal 
discomforts commonly complaint by diabetic patients (Zhao et al., 2003).   
Morphological changes in the small intestine appear to be a result of multiple physiological 
and metabolic changes. Increased intestinal growth in diabetes has been shown to correlate 
positively with increased hyperphagia which is undoubtedly a compensatory mechanism for 
the glucose loss in the urine (Thulesen et al., 1999). Additional mechanism however will be 
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the reported  increase in GLP-2 which possesses an intestine trophic effect. Immuno 
neutralization of the GLP-2 resulted in restoration of increased muscularis surface area 
observed in the proximal intestine of diabetic control animals (Hartmann et al., 2002). GLP-2 
has been shown to have no effect on food intake in experimental animals (Tsai et al., 1997). 
However plasma GLP-2 was shown to correlate with other factors that influence upper 
intestinal growth in diabetes such as dietary fiber (Thulesen et al., 1999). These findings 
suggest an influence of hyperphagia on GLP-2 secretion, both of which synergistically 
increase intestinal growth.  Inhibition of apoptosis has also been suggested to be one 
explanation for the observed increase in villi length and mucosal thickness in experimental 
diabetes (Noda et al., 2001). Whether the same factors are responsible for both lengthening of 
the villi and the whole intestine remain to be investigated. 
1.9.2   Metabolic changes in the small intestine during diabetes 
1.9.2.1 Glucose absorption and metabolism 
Diabetes mellitus is accompanied by changes in absorption and motor function of the small 
intestine (Ebert, 2005; Fujita et al., 1998). The accompanying  increase in postprandial 
glycaemia is continuously recognized as the major contributor to overall glycaemic control in 
type 2 diabetes (Ma et al., 2009). This increase in absorption is a result of the changes that 
occur at the brush border membrane (BBM) and basolateral membranes (BM) of the SI due 





-ATPase and glucose transporter 2 (GLUT2) (Fujita et al., 1998, Li et al., 2013). 
Furthermore, diabetic patients that develop neuropathic diabetes tend to have accelerated 
gastric emptying which correlate with accelerated intestinal absorption (Frank et al., 1995). 
Consequently, delaying gastric emptying for instance by opiate analgesics or prokinetic 
agents such as morphine resulted in decrease postprandial plasma glucose concentration in 
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type 2 diabetics (Gonlachanvit et al., 2003). As discussed  previously, a special function of 
the small intestine, intestinal gluconeogenesis,  is activated during diabetes and may 
contribute up to 35 % of total indigenous glucose production (Mithieux et al., 2004). Hence 
changes in intestinal glucose metabolism are important aspect of diabetic complications. 
1.9.2.2 Cholesterol and other lipids 
During diabetes, cholesterol biosynthesis is increased in all the segments of the small 
intestine. The increase in intestinal cholesterol biosynthesis in the early phase of diabetes may 
be attributed to increase in the activity of enzymes for the cholesterol synthesis. However, at 
later stages, the increase is mainly due to the hypertrophy of the small intestine (Feingold and 
Moser, 1984). Furthermore, cholesterol synthesis is increased more in the distal segment than 
the proximal segment of the small intestine. All the cells types on the villus-crypt axis in the 
distal segment show this  increase but is more pronounced in the cells found on the upper 
villus (Feingold and Moser, 1987). Moreover, conditions that lead to increase food intake 
such as obesity and pregnancy also lead to increased intestinal cholesterol synthesis (Feingold 
et al., 1986). This suggests that increased food intake associated with uncontrolled diabetes is 
the main stimulus for increased cholesterol synthesis. Not only was the level of indigenous 
synthesis observed to increase during diabetes, but also the rate of absorption and transport of 
dietary cholesterol. Further, the synthesis of intestinal triacylglycerols and transport via 
hepatic very low density lipoproteins (VLDL) into the circulation are also increased during 
diabetes. This increase in the transport of lipids from the small intestine in the form of 
chylomicrons may initiate changes in the lipid metabolism which may be important in 
atherosclerotic vascular disorders (Feingold, 1989). Collectively these changes in lipid 
metabolism constitute the central pathophysiologic feature of insulin resistance and T2D 
(Levy et al., 2010).  
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1.9.2.3 Hormonal secretion  
The role of the small intestine in blood glucose regulation was recognized after the 
observation that oral glucose caused a four times increase in blood glucose than intravenous 
glucose (DeFronzo et al., 1978). This led to the discovery of the gastrointestinal hormones 
responsible for the glucose dependent insulin secretion known as the incretin effect. The two 
known incretin hormones are glucose dependent insulinotropic hormone (GIP) secreted by 
the K-cells of the proximal small intestine and glucagon like peptide secreted by the L-cell of 
the distal ileum (Kazakos, 2011). The incretin effect has been shown to decrease during 
diabetes due to decrease action of GIP and reduced secretion of GLP-1 (Nauck et al., 1993a). 
The decreased action of GIP is attributed to the reversible β-cells insensitivity to circulating 
GIP which may be caused by hyperglycaemia. Because the action of GLP-1 is preserved in 
type 2 diabetes, continuous subcutaneous injection of the hormone was deemed to be an 
important therapeutic strategy (Nauck et al., 1993b). However as stated earlier, the action of 
both GIP and GLP-1 is short lived due to  their inactivation by dipeptidylpeptidase (DPP-4) 
making the only  alternative therapeutic strategy in incretin based therapies being either GLP-
1 agonists or DPP-4 inhibitors (Kazakos, 2011).  
1.10     OLEANOLIC ACID (OA) 
Oleanolic acid (3b-hydroxyolean-12-en-28-oic acid) (Figure 1.7) belongs to pentacyclic 
triterpenes class of biologically active compounds. It is highly ubiquitous and has been 
isolated from more than 1500 plant species, among which many are used as routine source of 
food and medicine. However, high content of OA in olive plant (Olea europae; family: 
oleaceae) serves as the major commercial source. OA exists in plants both as the free acid 
and part of glycoconjugates (saponins) that serve a defense function to the plants (Pollier and 




Figure 1.7: Oleanolic acid (adopted from Pollier and Goossens, 2012) 
The compound is increasingly attracting attention due its various pharmacologic actions. 
These include hepatoprotective effects, antioxidant, anti-inflammatory, anti-cancer and anti-
diabetic activities. The compound is clinically used alone or in combination with other drugs 
in the treatment of acute liver injury, chronic fibrosis and cirrhosis of the liver (Liu, 2005). 
Furthermore, OA has been shown by many researchers to be crucial in the management of 
diabetes mellitus (Castellano et al., 2013). The compound was shown to prevent visceral 
adiposity with a resulting improvement in glucose tolerance (de Melo et al., 2010). Oleanolic 
acid also improves organ sensitivity to insulin (Wang et al., 2013) and possesses 
antiglycative (Wang et al., 2010) and cardioprotective (Mapanga et al., 2012) properties in 
diabetic rats. Furthermore, OA inhibits the inflammatory and specific immune responses 
associated with islet allograft, thereby prolonging the survival of the cells (Nataraju et al., 
2009). Thus, the compound is of great interest to researchers as a possible candidate for the 
treatment of diseases especially diabetes.      
1.10.1 Mechanism of antihyperglycaemic action of oleanolic acid 
The hypoglycaemic properties of OA are also a result of its ability to prevent excess glucose 




Oleanolic acid was shown to inhibit liver gluconeogenesis and increase hepatic insulin 
sensitivity (Wang et al., 2011). The insulin sensitizer effects of OA can be partly explained 
by its ability to modulate insulin signaling cascade via protein tyrosine phosphatase 1B (PTP-
1B), which is an enzyme that deactivates insulin receptor.  Oleanolic acid binds to near the 
catalytic site of PTP-1B and in doing so inhibiting the enzyme and essentially increasing 
tissue insulin sensitivity (Ramírez-Espinosa et al., 2011). The antidiabetic actions of OA are 
also related to the ability of the compound to interfere with important processes in the 
etiology of diabetes such as oxidative stress, dyslipidemia and inflammatory responses. Wang 
et al. (2013) demonstrated that, OA stabilizes nuclear factor erythroid 2 p45-related factor 2 
(Nrf2) which is a crucial regulator in maintaining the pool of antioxidant enzymes. Moreover, 
the serum triglycerides, total cholesterol (TC), LDL-cholesterol and free fatty acids (FFAs) as 
well as the level of proinflammatory factors were shown to be reduced with OA treatment in 
type 2 diabetic rats (Wang et al., 2013). Treatment with OA also inhibits the small intestine 
uptake of glucose with a concomitant increase in glycogen biosynthesis in the intestinal wall. 
This may play a crucial role in decreasing postprandial glycaemia (Khathi et al., 2013). The 
β-cell-protective effects of OA against lipotoxicity and apoptosis is also important in 
maintaining normal insulin response to blood glucose level (Wang et al., 2011). 
Consequently, OA is also associated with decrease in diabetes associated pathologies such as 






1.11 RESEARCH JUSTIFICATION 
Diabetes is unarguably a morbid disease that needs to be controlled. Unfortunately, the 
pathogenesis and physiological changes that are associated with the disease are still not fully 
understood. Oleanolic acid has been shown to possess hypoglycaemic effects through 
different mechanisms. Further investigations are still needed to explore the full potential of 
the phytochemical. The specialized aspects of glutamine/glutamate metabolism of different 
glutamine-utilizing cells and the relationship of aspects of metabolism to cell function have 
been reported elsewhere (Newsholme et al., 2003). Hence elucidation of the correlation 
between oleanolic acid and glutamine metabolism in small intestine, the organ that utilizes 
the metabolite most vigorously, will give additional information on overall energy utilization 
in diabetic condition. This is fundamental to management of the disease.    
1.12 RESEARCH OBJECTIVES 
1.12.1   General Objective 
This research is aimed at investigating the effects of oleanolic acid on small intestine 
morphology and glutamine metabolizing enzymes in the small intestine of type 1 and type 2 
diabetic rats.  
 1.12.2   Specific Objectives 
a) To investigate the effects of oleanolic acid on histopathological changes occurring in the 
small intestine during diabetes.   
b) To investigate the effects of oral administration of oleanolic acid on the activities of 
phosphate dependent glutaminase, glutamate dehydrogenase, alanine aminotransferase and 
aspartate aminotransferase in the small intestine of streptozotocin induced type 1 and type 2 
diabetic rats. 
c) To determine the changes in the expression of glutaminase after OA treatment. 





Materials and Methods 
2.1 Chemicals and reagents 
Oleanolic acid (OA) was obtained from Shaanxi King Stone Enterprise, China. 
Streptozotocin, metformin, enzymes (L-glutamate dehydrogenase, lactate dehydrogenase and 
malate dehydrogenase all in buffered 50 % glycerol) , amino acids, α-ketoglutarate,  citric 
acid, sodium citrate, potassium phosphate dibasic (K2HPO4), potassium phosphate monobasic 
(KH2PO4), hydrochloric acid,  TRIZMA base, potassium chloride, PMSF, benzamidine, 
bovine serum albumin (BSA), hydrazine, β-nicotinamide adenine dinucleotide (NAD
+)
, β-





adenosine-5'-diphosphate (ADP), perchloric acid, triethanolamine hydrochloride (TEA), 
ammonium acetate, EDTA, DMSO, formalin, xylene, hematoxylin dye and BCPI/NBT 
premixed liquid substrate were purchased from Sigma, St Loius, MO, USA. Eosin dye, 
copper (II) sulphate pentahydrate (CuSO4.5H2O) and potassium sodium tartarate 
(KNaC4H4O4.H2O) were obtained from SAARCHEM, Krugersdorp, South Africa. Absolute 
ethanol, potassium hydroxide and potassium iodide were obtained from Merck Millipore, 
Darmstadt, Germany. All SDS-PAGE chemicals and secondary antibody (goat anti-rabbit 
IgG alkaline phosphatase conjugate were obtained from Bio-Rad, Hercules, California, USA. 
Primary antibodies anti-rabbit IgG kidney-type glutaminase antibody (KGA/PDG) was from 
Santa Cruz Biotech USA and anti-rabbit IgG β-actin antibody which acted as the loading 
control was purchased from BioLegend, San Diego, USA. Insulin (Humalog KwiPen) was 




Male Sprague-Dawley rats (200-250 g body weight) were procured from the Biomedical 
Resource Unit (BRU) at Westville Campus of the University of KwaZulu-Natal, South 
Africa. Drinking water and feed (commercially available rat chow diet) were provided for the 
animals ad libitum for the period of the experiment. Handling and maintenance of the animals 
were according to the rules and regulations of the animal ethics committee of the University 
(Ethics approval reference: 001/14/Animal. See appendix 1). 
2.3 Animals Grouping, Induction of Diabetes and Treatment 
The animals for the studies were randomly grouped as depicted in Figures 2.1A and 2.1B for 
type 1 and type 2 diabetes studies respectively. 
Diabetes was induced by a single intraperitoneal injection of streptozotocin dissolved in 
freshly prepared 0.1 M citrate buffer pH 4.5 at doses of 60 mg/kg body weight or 40 mg/kg 
bw for type 1 or type 2 respectively. Control animals were injected with the buffer only. One 
week after the treatment, blood glucose concentrations were determined. A fasting blood  
glucose concentration  of 18  mmol/L or above was considered as a stable diabetic state for 
type 1 diabetes whereas concentrations of 7-14 mM/L was considered as a stable diabetic 
state for type 2 diabetes The blood for glucose determination was collected from the tail vain 
of the rats (approximately 50 µl) and measured using Glucometer (Accu-chek performa nano, 
USA).      
All treatment drugs at the stated doses (Figure 2.1A and 2.1B) were dissolved in 50 % DMSO 
and administered orally except for insulin which was subcutaneous. The treatments lasted for 
fourteen days after which the animals were sacrificed using halothane anesthesia and the 




2.4 Experiment design 
 
 






2.5 Intestine sampling 
The abdomen of the sacrificed rats was immediately cut open, and the small intestine 
removed from the abdomen cavity. Duodenum was considered as first 10 cm beyond the 
pylorus. The middle 15 cm of the remaining segment was obtained as the jejunum and the 
bottom 3.5cm as the ileum (DeSesso and Jacobson, 2001).  The intestinal sections were then 
rinsed using physiological saline solution and 1cm of each part was preserved in 10 % 
formalin. The rest of the jejunum was frozen at liquid nitrogen temperature and stored at -20 
0
C until use.  
Prior to enzyme assays, the frozen intestines were thawed and homogenized (5 ml/mg tissue)  
in buffer (50 mM Tris and 120 mM KCl, 0.5 mM PMSF and 5 mM benzamidine pH 7.4) 
using Omni homogenizer, USA. 
2.6 Enzyme assays 
2.6.1 Phosphate dependent glutaminase (PDG) 
Preparations: Buffer A (10 mM K2HPO4, 50 mM TRIZMA base, 120 mM KCl, pH 8.6), 
buffer B (50 mM Tris, 310 mM hydrazine, pH 9). 
The enzyme was assayed at 37 
0
C as described by Curthoys and Weiss (1974) with 
modifications by Masola and Zvinavashe, (2003). The two step procedure involves the 
determination of the amount of glutamate formed by PDG using glutamate dehydrogenase 
(GDH) (Figure 2.2). The reaction mixture contains the following in final concentrations; 
freshly prepared 20 mM glutamine (in buffer A) and 2 mM NAD
+
 + 0.25 mM ADP (in buffer 
B). 50 µl sample was added to 200 µl buffer A with glutamine except for the blank which 
contains equal volume of buffer only. The mixture was incubated for 15 min at 37 
0
C. The 
reaction was terminated by deproteinization with 120 µl of 30 % perchloric acid and the tubes 
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vortexed and placed on ice for 5 min. 225 µl KOH was subsequently added and the mixture 
brought to room temperature before adding 2 ml buffer B (with freshly added NAD
+
 + ADP). 
The mixture was centrifuged at 3000 rpm for 5 min. Oxidation of glutamate was initiated by 
the addition of 10 µl GDH (13 units) in 50 % glycerol and incubating for 45 min at room 
temperature. The amount of NAD
+
 reduced to NADH was estimated sphectrophotometrically 
at 340 nm using Varian Cary 50 UV/Vis Spectrophotometer, SMM Instruments Midrand, 
South Africa. Calculations of enzyme activity were carried out using a NADH millimolar 








Figure 2.2:  Assay of Phosphate dependent glutaminase (PDG) activity 
2.6.2 Glutamate dehydrogenase (GDH), aspartate aminotransferase (ALT) and alanine 
aminotransferase (AST) 
The activities of GDH, AST and ALT were determined at 25 
0
C as adapted by Masola et al. 
(2008). 
GDH activity was estimated in the direction of glutamate formation (Figure 2.3) by following 
the oxidation of NADH spectrophotometrically at 340 nm (Schmidt, 1974). The reaction 
mixture contains the following in final concentrations: buffer mixture (50 mM 




Figure 2.3: Assay of glutamate dehydrogenase (GDH) activity 
ammonium acetate/2.5 mM EDTA, pH 8), freshly prepared mixture of 1 mM ADP/0.2 mM 
NADH/8.6 units ml
-1
 lactate dehydrogenase and 0.2 ml of sample. The absorbance is then 
read at 340 nm to the total consumption of the pyruvate. Thereafter, the reaction is started by 
the addition of 7 mM α-ketoglutarate in buffer in a final volume of 3 ml. 
 
Figure 2.4: Assay of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
activity 
ALT (AST) activity was determined by coupling the reaction to the reduction of generated 
pyruvate (oxaloacetate) by lactate dehydrogenase (malic dehydrogenase) as shown in Figure 
2.4. The rate of oxidation of NADH in the reduction reaction is measured at 340 nm 
(Volmann-Mitchell and Parsons, 1974). The reaction mixtures contain the following in final 
concentrations: 0.1 M sodium phosphate buffer pH 7.6; 7 mM α-ketoglutarate in buffer; 0.2 
mM NADH in buffer; 8.6 units/ml L-lactic dehydrogenase (LDH) (or 19 units/ml malic 
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dehydrogenase [MDH] for AST) in 50 % glycerol. This is followed by the addition of 0.1 ml 
sample. Non-specific oxidation of NADH is then recorded. The reaction is thereafter started 
by the addition of 33 mM L-alanine (or L-aspartate for AST) in buffer in a final reaction 
volume of 3 ml.   
Specific activity of GDH, ALT and AST are expressed in nmoles of NADH oxidized per min 
per mg sample protein taking the millimolar extinction coefficient of NADH at 340 nm as 
6.22 M-1cm-1. 
2.6.3 Hexokinase (HK) 
Hexokinase activity was determined at 30 
0
C using the method described by Goward et al. 
(1986) with modifications by Ngubane et al. (2011). The assay involves estimation of 
glucose-6-phospahate produced by HK as it is oxidized by glucose-6-phophate 
dehydrogenase with concomitant reduction of nicotinamide adenine dinucleotide phosphate 
(NADP
+
) (Figure 2.5). The reaction mixture contains the following in final concentration: 20 
mM TEA-HCl buffer (pH 7.6); glucose (222 mM); MgCl2 (8 mM); NADP
+ 
(0.91 mM); ATP 
(0.64 mM); mercaptoethanol (5 mM) and 0.55 Uml
-1 
glucose-6-phosphate dehydrogenase. 
The reaction was initiated by the addition of 100 µl sample and the appearance of NADPH 
was followed sphectrophotometrically for 10 min at 340 nm. 
 
Figure 2.5: Assay of hexokinase activity. 
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2.7 SDS-PAGE and western blotting 
Preparations: Sample buffer (v/v 32.5 % deionized water, 12.5 % 0.5 M Tris-HCl, 25 % 
glycerol, 20 % SDS, 2 % bromophenol + 0.5 % mercaptoethanol prior to use), running buffer 
(30.3 g Tris base, 144 g glycine, 10 g SDS diluted 1:10 prior to run), resolving gel (v/v 41 % 
deionized water, 33 % acrylamide/bisacrylamide, 25 % 1.5 M Tris-HCl buffer, 1 % SDS + 50 
µl APS + 5 µ TEMED/10 ml), Stacking gel (v/v 41 % deionized water, 33 % 
acrylamide/bisacrylamide, 25 % 0.5 M Tris-HCl buffer, 1 % SDS + 50 µl APS + 10 µ 
TEMED/10 ml), butanol:water (1:1 v/v), fixative (40 % methanol + 7 % acetic acid), transfer 
buffer (25 mM Tris, 150 mM glycine, 20 % v/v methanol), TBS-tween buffer (200 mM Tris, 
500 mM NaCl, 0.05 % Tween 20), blocking buffer (5 % w/v nonfat dried milk in TBS-tween 
buffer). 
SDS-PAGE was performed using standard lab procedure for electrophoretic separation of 
proteins. Resolving gel was degassed and loaded into the wells, covered with butanol:water 
and allowed to polymerize for 45-60 min. After pouring away the butanol:water layer, the gel 
was washed with deionized water and dried. Degassed stacking gel was loaded and the comb 
positioned. The stacking gel was allowed to polymerize for 15-30 min after which the comb 
was removed and the gel washed and dried. The gel was placed in the electrophoretic 
chamber containing the running buffer. Protein samples (50 µg) and 5 µl of molecular marker 
were subsequently loaded and separated at 100-150 V (Mini-PROTEAN 3 Cell, Bio Rad. 
South Africa). After separation, the gels were used for staining or blotting.    
The gel was fixed for 30 min and stained in commassie stain for 30-45 min on a rocker. The 





2.7.1 Glutaminase blotting 
The gel was sandwiched into the cassette in the following order starting from the black colour 
side: filter pad, filter paper, gel, nitrocellulose membrane, filter paper, filter pad. The proteins 
were then transferred from the gel to nitrocellulose membrane at 100 V for 2 hr in the 
electrophoresis chamber (Mini Trans-Blot Cell, Bio-Rad, South Africa) containing the 
transfer buffer. After the transfer was completed, the nitrocellulose membrane was placed in 
blocking buffer overnight at 4 
0
C.  
Primary antibody was diluted 1:500 (or 1:1000 depending on the   primary antibody) in 
blocking buffer and overlaid on the nitrocellulose membrane and gently shaken for 1 hr at 
room temperature. The membrane was washed 3 times with TBS-tween buffer for 5 min 
each. The procedure was repeated with the secondary antibody except no blocking buffer was 
used in the final washing. Finally BCIP/NBT solution was added as the substrate and exposed 
until colour development and washed with deionized water.  
For the dot blot analysis, 20 µg of proteins from each sample were spotted and allowed to air-
dry. The blocking and addition of antibodies were 30 min each while the washing step was 
same as above. The bands were visualized using a Syngene G-BOX Chem XR5, Vacutec 
(South Africa) and  GeneTools analysis software was used to quantify  the bands.  
2.8 Determination of protein concentration 
Protein concentration was estimated using biuret assay (Gornall et al. 1949). The biuret 
reagent was prepared by first dissolving 0.3 % CuSO4.5H2O and 0.9 % KNaC4H4O4.H2O in 
500 ml of 0.2 M NaOH, followed by the addition of 0.5 % of KI and the volume made up to 1 
liter with the solvent. Protein standards (concentration 0-10 mg/ml) of bovine serum albumin 
(BSA) were prepared. 3 ml of the biuret reagent was added to 2 ml final volume of protein 
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samples. The resulting solution was mixed and incubated for 10 min at 37 ⁰C in a water bath. 
The tubes were cooled and the absorbance was read at 540 nm. Readings from the protein 
standards were plotted against their known protein concentrations (see appendix 2) and the 
unknown protein concentrations were interpolated from the standard curve.   
2.9 Histopathological studies 
Histopathological studies was done using the standard laboratory protocol for paraffin 
embedding. The intestinal segments fixed in 10 % formalin were dehydrated in increasing 
concentration (50 %-90 %) of ethanol and finally xylene. The tissues were then oriented 
longitudinally and cross-sectionally and embedded in paraffin wax. 4 µm of sections were cut 
using a microtome. The slides were allowed to dry overnight and then deparaffinized in p-
xylene and rehydrated in gradients of ethanol (100 %, 80 %, 70 %, and 50 %) and rinsed in 
water. The slides were immediately stained for 5 min in hematoxylin stain and rinsed with 
water followed by counterstaining in eosin for 3 min. The slides were then mounted in DPX, 
cover-slipped and allowed to settle and dry for two days before scanning using Leica 
SCN400, Germany (Software version: SlidePath Gateway Client Viewer 2.0). 
2.10 Data analysis 
All data were expressed as means ± standard deviation (SD). Statistical analysis was done 
using Graph Pad InStat Software (version 4.00, Graph Pad Software, San Diego, California, 
USA). Statistical comparison among groups was done using one-way analysis of variance 
(ANOVA) followed by Turkey-Kramer multiple comparison test. Value of p < 0.05 






3.1      Type 1 diabetes 
3.1.1 Confirmation of diabetes 
Fasting (12 hr) blood glucose (FBG) was determined one week after induction with 60 mg/kg 
body weight STZ for the confirmation of type 1 diabetes. Additional FBG was determined at 
the end of the two week treatment period. All groups of diabetic rats were above 18 mmol/L 
throughout the experiment period whereas the non-diabetic groups maintained a normal range 
of fasting blood glucose as indicated in the methods section. 
3.1.2 Change in body weight and small intestine morphometry  
3.1.2.1 Body weight and relative small intestine weight 
Figure 3.2A shows the body weight change for type 1 diabetic rats and how it is affected by 
OA treatment compared to non-diabetic groups. One week after induction of type 1 diabetes 
all diabetic rat groups lost 6-9 % of their baseline weight. On the other hand, the non-diabetic 
groups gained 7-9 % of their initial weights. However, after two weeks of treatment, both 
diabetic and non-diabetic groups gained weight. Weight gained is lower (3-11 %) in all 
diabetic groups compared to the non-diabetic groups (15-27 %). OA treatment of non-
diabetic rats led to higher weight gain (27 %) among all groups while insulin treatment of 
diabetic rats significantly (P<0.05) ameliorated weight loss. 
The weight of the small intestine expressed per gram body weight (BW) was increased 
significantly (p<0.05) in all type 1 diabetic groups compared to the NC group (Figure 3.2B). 
Moreover, all non-diabetic drug-treated groups (NOI, NI, NOI)) also showed increased 
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intestinal weight expressed per g BW compared to NC group although not statistically 
significant (p>0.05). The value of 0.0352 g/g BW obtained for NO
 
group is relatively higher 
than those obtained for NI (0.03415 g/g) and NOI (0.0323 g/g) groups. Furthermore, the 
weight of SI expressed per unit length was relatively similar in both the diabetic and non-
diabetic groups when expressed per g BW (Figure 3.2B). The circumferential area (Figure 
3.1) of the intestine from diabetic rats was also increased significantly in all segments 
compared to the non-diabetic groups as shown in Figure 3.1C. Treatment with insulin or 
insulin + OA tended to have some ameliorative effects in the duodenum (not significant) and 
ileum (significant for the DOI group) but not in the jejunum.   
 
                                            
                                                    
                
Figure 3.1: H&E stain of SI showing elongated villi in DC jejunum (A) compared to NC 
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Figure 3.2: Effects of diabetes and treatments on body weight and SI weight (A) Body 
weight change (B) Relative SI weight per g body weight/per unit length (C) SI 
circumferential area. Results are expressed as means ± SD (n = 5-6). Different alphabets (a-c) 






3.1.2.2 SI morphometry  
The average villus length and surface area increases from duodenum and jejunum down to 
the ileum (Figure 3.3A). However this trend was altered in some groups, most noticeably in 
the non-diabetic group treated with OA (NO group). In this group, the villi were significantly 
(p<0.05) longer and broader in the jejunum than the duodenum and ileum (Figure 3.3B). 
Moreover, this increase in the surface area of the jejunal villi was almost 300 % compared to 
the NC group. Furthermore, in terms of surface area all diabetic groups also have 
significantly larger villi in the duodenum and jejunum except for the duodenum of DOI group 
which was within NC range as shown in Figure 3.3B. The villi in the ileum of all groups were 
not significantly affected except for NOI group which appeared broader. 
Average mucosal height (average villus height + average crypt depth) was visually (Figure 
3.1) and significantly increased in the duodenum and jejunum of diabetic rats as well as NO 
and NOI groups compared to the NC group. The average crypt depth was not adversely 
altered in all SI segments among groups, hence the significant increase in mucosal height in 



























































































































Figure 3.3: Effects of diabetes and treatments on villi appearance (A) Pattern of villi length 
along the segments of the SI (B) Average villus surface area in the SI segments. Results are 
expressed as means ± SD (n = 5-6). Different alphabets (a-d) on a chart indicates significant 
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Figure 3.4: Effect of diabetes and treatments on average crypt depth, average villi length and 
average mucosal height in (A) Duodenum (B) Jejunum (C) Ileum. Results are expressed as 
means ± SD (n = 5-6). Different alphabets (a-d) on a chart indicates significant (p<0.05) 







The change in total muscular thickness (comprising the layers from muscularis externae to 
the serosal side) is presented in Figure 3.5.  The change in thickness was only significant 






































































Figure 3.5: Effects of diabetes and OA treatment on muscular thickness. Results are 
expressed as means ± SD (n = 5-6). Different alphabets (a-b) on a chart indicates significant 




Table 3.1 shows the number of goblet cells (GC) per villus in the SI segments of each of the 
groups. Diabetes resulted in significant (p<0.05) increase in number of GC per villus. This 
increase was significantly (p<0.05) reduced in the duodenum and ileum of diabetic rats 
treated with insulin and in the jejunum and ileum the DOI group. Insulin treatment of normal 
rats resulted in elevated number of GC per villus in all segments of the SI and this is 
significant (p<0.05) in the duodenum. 
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Table 3.1: Effects of diabetes and treatments on SI goblet cells 
Results are expressed as means ± SD (n = 5-6). Different alphabets (a-b) along a row 
indicates significant (p<0.05) difference (Turkey’s range post hoc test). 
 
3.1.3 Enzymes activity and glutaminase expression 
Diabetic groups and non-diabetic treated groups tended to have slight but significant (p<0.05) 
decrease in phosphate dependent glutaminase (PDG) activity compared to the NC group 
(Figure 3.6A). The expression of PDG in all groups is not altered to an extent detectable by 
dot blot analysis (Figure 3.6B). The initial attempt was to quantify the expression using 
western blot as there was good protein distribution in the samples (appendix 3). However, an 
unidentified problem that was most likely related to the new blotting paper acquired by the 
laboratory  did not allow successful western blot. The problem is still being investigated with 
the supplier. Off-cut strips from the old blotting paper were used for the dot blots and the 
result in Figure 3.6C (and Figure 3.13C) was obtained.  
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Figure 3.6: Effect of diabetes and treatments on PDG activity and expression. (A) PDG 
activity. Results are expressed as means ± SD (n = 4). The alphabet (a) on the chart indicates 
significant (p<0.05) difference (Turkey’s range post hoc test) from other groups. (B) Dot 
blots (15 µg protein was loaded for each dot). The product of a house-keeping gene β-Actin 
acted as the loading control. (C) PDG expression normalized with β-Actin. 
 
On the other hand, the SI activities of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were both significantly elevated in the DC
 
compared to the NC
 
group 
(Figure 3.7A). The activity of ALT was significantly (p<0.05) decreased in the DO, DI and 
DOI groups compared to the DC
 
group. Moreover, the treatments in the diabetic groups were 
able to reduce AST activity and this decrease was significant (p<0.05) except for the DO 








AST activity compared to the NC group and this is significant (p<0.05) in the case of ALT. 
On the other hand, SI glutamate dehydrogenase (GDH) activity was elevated more than 100 




























































































Figure 3.7: Effect of diabetes and treatments on SI enzymes activity (A) ALT and AST (B) 
GDH. Results are expressed as means ± SD (n = 4). Different alphabets (a-c) on a chart 






The activity of hexokinase (HK) was slightly decreased in the NI, NOI and DI groups and 
slightly increased in the DC and DO groups although not statistically significant compared to 
the NC group (Figure 3.8). However there was a significant increase in the DOI group which 











































Figure 3.8: Effect of diabetes and treatments on hexokinase activity. Results are expressed as 
means ± SD (n = 4). Different alphabets (a-d) on a chart indicates significant (p<0.05) 




3.2 Type 2 diabetes 
3.2.1 Confirmation of diabetes 
Fasting (12 hr) blood glucose was determined one week after induction with 45 mg/kg body 
weight STZ for the confirmation of type 2 diabetes. Additional FBG was determined after 
two weeks of the treatment period. All groups of diabetic rats were within 7-14 mmol/L 
throughout the experiment period whereas the non-diabetic groups maintained a normal range 
of fasting blood glucose as indicated in the methods section. 
3.2.2 Change in body weight and small intestine morphometry  
3.2.2.1 Body weight and relative small intestine weight  
Data on changes in body weights one week after induction and after treatment for type 2 
diabetic rats is presented in Figure 3.9A. All groups gained weight 1 week after induction but 
the weight gain in non-diabetic groups is higher than in diabetic groups. At the end of the two 
weeks treatment, the NC and NO
 
groups gained 10 % and 19% respectively of while the DC 
and DO diabetic groups gained 0-4 % of their initial weights. There was a slight weight loss 
in the DM group.  
The relative SI weight expressed per BW or unit length for the type 2 diabetic rats is 
presented in Figure 3.9B. Both parameters were increased significantly (p<0.05) in all 
diabetic groups and insignificantly (p>0.05) in the NO group compared to the NC
 
group. 
Moreover, the circumferential area of the SI of NO and diabetic groups is increased most 
notably around the jejunum as depicted in Figure 3.9C. The jejunum appeared significantly 
(p<0.05) wider in all diabetic groups compared to NC. The width of the duodenum is 
increased significantly (p<0.05) only in the DC and DM groups while the ileum is 
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Figure 3.9: Effects of diabetes and treatments on body weight and SI weight (A) body weight 
change (B) Relative SI weight per g body weight/per unit length (C) SI circumferential area.  
Results are expressed as means ± SD (n = 5-6). Different alphabets (a-c) on a chart indicates 







3.2.2.2 SI morphometry:  
The average villus length increases from duodenum through the jejunum down to the ileum 
(Figure 3.10A). This pattern was not affected in all diabetic groups but OA treatment of 
normal rats grossly increased jejunal villi length  and significantly increased  surface area as 
well (Figure 3.10B). Moreover, the average villus surface area in all segments was not altered 
in the DC and DO groups but was significantly (p<0.05) increased in the DM group. 
Average mucosal height (average villus height + average crypt depth) was not affected in the 
duodenum and ileum of both DC and DO groups (Figure 3.11 A&C). However, the mucosa is 
significantly (p<0.05) longer in the jejunum of DC compared to NC (Figure 3.11B). This was 
reduced by OA treatment of diabetic animals. Mucosal height is significantly higher (p<0.05) 
in all SI segments of DM group compared to NC. Moreover, OA treatment of non-diabetic 
rats (NO groups) resulted in significantly longer duodenal and jejunal mucosa compared to 
NC group. The average crypt depth was slightly decreased in the duodenum of DC and DO 
groups and ileum of DO groups compared to NC. Furthermore slight elevation of crypts was 
observed in jejunum of NO and DM groups as well as the ileum of DM group compared to 
NC. However, in all cases of significant mucosal height change, increase villi length is 
responsible for at least 80 % of the increase.   
Table 3.2 shows the number of goblet cells per villus in the SI segments of each of the 
groups. Goblet cells per villus were significantly (p<0.05) elevated in all segments in the DM 













































































Figure 3.10: Effects of diabetes and treatments on villi appearance (A) Pattern of villi length 
along the segments of the SI (B) Average villus surface area in the SI segments. Results are 
expressed as means ± SD (n = 5-6). Different alphabets (a-b) on a chart indicates significant 
(p<0.05) difference (Turkey’s range post hoc test). 
 
Table 3.2: Effects of diabetes and treatments on SI goblet cells  
Results are expressed as means ± SD (n = 5-6). Different alphabets (a-b) along a row 
indicates significant (p<0.05) difference (Turkey’s range post hoc test). 
 DUODENUM 
NC NO DC DO DM 








































































































































Figure 3.11: Effect of diabetes and treatments on average crypt depth, average villi length 






as means ± SD (n = 5-6). Different alphabets (a-c) on a chart indicates significant (p<0.05) 
difference (Turkey’s range post hoc test). 
 
The change in total muscular thickness (comprising the layers from muscularis externae to 
the serosal side) is presented in Figure 3.12.  The change in thickness was only significant 
(p<0.05) in the duodenum of DM group, jejunum of NO and DO groups and ileum of DC and 























































Figure 3.12: Effects of diabetes and treatments on muscular thickness.  Results are expressed 
as means ± SD (n = 5-6). Different alphabets (a-c) on a chart indicates significant (p<0.05) 
difference (Turkey’s range post hoc test). 
 
3.2.3 Enzymes activity and glutaminase expression 
Glutaminase activity was slightly decreased in the DC group but this decrease was 
insignificant (p>0.05) compared to the NC group as shown in Figure 3.13A. The expression 
of PDG was also not different to a large extent as detected by dot blots (Figure 3.13B). 
Treatment with OA of both non-diabetic and diabetic groups significantly (p<0.05) decreased 





























































Figure 3.13: Effect of diabetes and treatments on PDG activity and expression. (A) PDG 
activity. Results are expressed as means ± SD (n = 4). Different alphabets (a-c) on a chart 
indicates significant (p<0.05) difference (Turkey’s range post hoc test). (C) Dot blots (15 µg 
protein was loaded for each dot). The loading control was β-actin. (C) PDG expression 
normalized with β-actin. 
On the other hand, diabetes caused a significant increase in ALT and AST activity and this 
increase was reduced by treatment with OA or metformin particularly with respect to ALT 
whose levels were reduced to those found in the normal animals (Figure 3.14A). GDH 
activity was also significantly increased by diabetes and this increase was reduced by 
treatment with OA or metformin, the reduction being significant with the latter treatment 















































































Figure 3.14: Effect of diabetes and treatments on SI enzymes activity (A) ALT and AST (B) 
GDH. Results are expressed as means ± SD (n = 4). Different alphabets (a-c) on a chart 
indicates significant (p<0.05) difference (Turkey’s range post hoc test). 
The SI hexokinase activity was decreased in the DC group although this was not significant 
compared to NC group (Figure 3.15). Moreover, OA treatment in both NO and DO group did 
not significantly affect HK activity although there was a slight increase in activity in the DO 
group compared to NC. The HK activity in the DM group was significantly (p<0.05) higher 






































Figure 3.15: Effect of diabetes and treatments on hexokinase activity. Results are expressed 
as means ± SD (n = 4). Different alphabets (a-b) on a chart indicates significant (p<0.05) 




  CHAPTER FOUR 
Discussion 
4.1 Type 1 Diabetes 
Prevention of weight loss by treatment of diabetic rats with oleanolic acid alone and in 
combination with insulin has been reported in a 5 weeks study on STZ induced diabetic-rats 
(Musabayane et al., 2010). In the present study, both NO and NOI groups gained relatively 
higher weight compared to NC (Figure 3.1A) which may suggest OA-induced tissue growth 
even in the absence of diabetes.  Because OA has not been previously reported to induce 
increased food consumption or water intake in various rat models (Musabayane et al., 2010; 
Raphael and Khuttan, 2003; Wang et al., 2010), increased nutrient consumption could not 
explain the weight gain. Hence, OA may induce tissue growth via a different mechanism such 
as increased delivery of energy source into the cells. The short duration of the present study 
did not allow for optimum time to observe increased weight gain in diabetic animals as 
reported by Musabayane et al. (2010).  
Increased weight and length of the small intestine have been noticed in other studies on 
animal models of diabetes (Diani et al., 1976; Schedl and Wilson, 1971). This has been found 
to be both a result of hyperplasia and hypertrophy of the SI (Nakabou et al. 1974). In this 
study, all treatments were not able to prevent increase in both parameters (weight and length) 
(Figure 3.1B). This could be due to the fact that increased intestinal weight and length occur 
in the early stages of chemical-induced diabetes. Significant SI weight and length increases 
were reported to occur as early as 8 days post diabetes induction (Schedl and Wilson, 1971). 
Hence the one week window period given for the confirmation of diabetes may have induced 
an intestinal growth effect that cannot be reversed in the two weeks treatment period. The 
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significant reduction observed on the increased circumferential area in the ileum of DOI 
group and slight decrease in duodenum and ileum of DI group suggest that SI segments 
respond to treatment differently due to their metabolic specialization. This could be 
attributable to the absorptive nature of the jejunum since hyperphagia induced by diabetes has 
been suggested to be a trigger of intestinal growth (Thulesen et al. 1999). It is important to 
mention at this point that hyperphagia is just one of a number of explanations given for 
increased SI growth none of which is yet conclusive (Zhao et al. 2003). These include a 
glucagon like peptide-2 (GLP-2) -which possesses SI trophic effects- mediated mechanism. 
In line with this theory, GLP-2 level has been observed to be elevated in diabetic condition 
(Fischer et al., 1997). Hence multiple factors are likely to be responsible for the observed 
effects of diabetes on the SI. 
The morphometric data also seem to suggest the proximal SI (jejunum and the duodenum) to 
be the main site of diabetes induced SI changes as observed in the significant increase in 
mucosal and villi length and surface area in all diabetic groups around the jejunum (Figure 
3.4A-C). The villi in the ileum are not affected by either treatments or diabetes and this could 
be attributed to its minimal or no function in nutrient absorption. On the other hand, 
surprisingly profound increase in length and surface area of jejunal villi of normal rats with 
OA treatment is reported here for the first time. Increased food as well as increased glucose 
(and other nutrients) absorption as given in the explanation for diabetes-induced mucosal 
changes could not however account for the OA-induced villi changes in normal rats for the 
following reasons: 1) as stated earlier, OA has not been reported to increase nutrient uptake 
2) although OA induces gross villi changes, the whole intestinal weight or length was only 
slightly affected by OA treatment suggesting minimal hypertrophy. These suggest an entirely 
different mechanism of OA-induced villi changes in the SI. Suppression of apoptosis in a 
caspase 3-related mechanism has also been suggested for diabetes induced SI changes (Noda 
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et al., 2001).  However, various reports suggest that OA and other pentacyclic triterpenes do 
not affect caspase-3 in intestine IEC-6 and IEC-18 cell lines (Reyes et al. 2006) as well as 
liver L-02 cell lines  (Yan et al., 2010). Hence,  mechanisms that have been investigated for 
SI hypertrophy and villi changes could not account for OA induced changes in the SI of 
normal rats. Another putative mechanism that has not been yet investigated is the inhibitory 
effects of OA (Takada et al., 2010) on the apoptotic tumor necrosis factor-α (TNF-α) which is 
known to induce small intestine damage (Fukumoto et al., 2011, Matsumoto et al., 2006). If 
OA does inhibit TNF-α in the mucosal cells to any significant extent, it will be expected to 
induce mucosal hyperplasia as observed in the present study. 
The actual causes of increased muscular stiffness induced by diabetes have not been yet 
elucidated conclusively. However, orientation and content of collagen of the SI wall (Fung, 
1993) as well as collagen glycation (Kandemir et al., 1995) have been implicated for the 
effect. In another study, increased advanced glycation end products (AGEs) and receptors for 
advanced glycation end products (RAGEs) were detected in type 1 diabetic rats (Chen et al., 
2012). Hence, the observed significant decrease in muscular thickness in all diabetic treated 
groups may be related to the decreased circulating glucose with minimal collagen glycation 
that occurred with the treatments.  
Diabetes has been reported to increase the number of goblet cells per villus (Mantle et al., 
1989) as confirmed by this study. Increased in number of goblet cells as well as mucin 
secretion has been reported to be associated with many gastrointestinal diseases such as 
zoonotic infections (Kim and Khan, 2013), carcinoma and inflammatory bowel disease 
(Filipe et al., 1979, Reid et al., 1984). However, diabetes appeared to affect only the number 
of goblet cells per villus but mucin content per tissue was decreased (Mantle et al., 1989). 
Therefore, diabetes affects goblet cells function differently from other GI diseases. Although 
no conclusion can be drawn on the actual cause of increased number of goblet cells, factors 
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such as hyperphagia that cause alterations in villi size have been implicated (Mantle et al. 
1989). However, in the present study, OA treatment of normal animals has also resulted in 
larger villi but the number of goblet cell per villus is not different from the normal control. 
This is not surprising since OA does not lead to hyperphagia in normal animals and hence the 
non-elevation in number of goblet cells per villus in the NO group. Moreover, the rise in 
number of GC per villus has not been attributed to hyperglycaemia and this study also seems 
to supports this assertion. The significant rise in GC number per villus in normal rats treated 
with insulin suggest a mechanism other than hyperglycaemia (and increase in villi size 
probably) for elevated GC. However the implication of increased villus size is depicted in the 
DC, DO and DOI which have high GC per villus as well as larger villi compared to the DI 
group which has lower of both (Table 3.1). But even this is refuted by the above mentioned 
observation with NO group. Hence, more studies to elucidate the actual cause in alteration in 
number of GC per villus in relation to glucose level and of course diabetes are therefore 
needed for conclusive information. 
The activity of PDG could be increased greatly under prolonged fasting and uncontrolled 
diabetes in accordance with its role in SI gluconeogenesis under these conditions (Mithieux et 
al., 2004).  However, slight decrease to no effect was observed in early stages of fasting and 
diabetes as reported in this study (Hartmann and Plauth, 1989; Nagy and Kretchmer, 1986). 
The rate limiting step for PDG catalyzed reaction was suggested to be the deamidation step 
and not the removal of the product (glutamate) (Hartmann and Plauth, 1989). In another study 
a normal mitochondrial PDG from SI was able to generate glutamate in a concentration more 
than what can be handled by the aminotransferases (ALT and AST) responsible for the 
greater part of its subsequent metabolism (Masola et al., 1985). These imply that, increased 
glutamate utilization can occur without affecting PDG activity under different metabolic 
states. Essentially this indicates that increased aminotransferase activity may occur as a result 
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of conditions such as diabetes without significant alteration in PDG activity. Furthermore, the 
observed decrease in diabetes-induced increased ALT and AST activities in the DO and DOI 
groups as well as slight increase in HK activity in the DOI group is not directly explainable in 
terms of OA’s ability to induce glucose removal from the circulation as in the case of insulin 
(Figure 3.6 A&C). The insulin effects on HK may be explained by the increased utilization of 
glucose in other tissues making the intestine less important as site of glucose disposal. 
Consequently, reduced cytosolic pyruvate from glycolysis for transamination with available 
glutamate explains decreased ALT activity with insulin treatment. However, in the case of 
OA treatment, disparity was observed in HK activity in relation to ALT and AST activities. 
Increase in HK activity was maintained or even increased (in DOI group) with OA treatment 
while increased ALT and AST activities were reduced. The implication is that, some of the 
glucose-6-phophate generated by HK is being committed to other pathways (glycogen 
synthesis or pentose phosphate pathway). Hence, oleanolic acid treatment maintains the 
importance of small intestine as a site of excess glucose disposal (even in the presence of 
insulin) while decreasing diabetes-induced elevated ALT and AST activities. This 
observation further confirms a synergistic relationship between OA and insulin in alleviating 
diabetes.  
Flux through intestinal glutamate dehydrogenase is known to be minimal and less important 
than the aminotransferases pathway for glutamate utilization (Newsholme and Carrie, 1994). 
However, under conditions such as starvation, generation of ammonia from glutamate in the 
intestine has been reported to be increased as an adaptive mechanism for modulating redox 
potential of the whole body (Souba, 1993). Hence, the GDH pathway could also be increased 
(and important) in diabetes to generate more ammonia for redox control of diabetes induced 
ketoacidosis. The α-ketoglutarate generated by the reaction can be converted to oxaloacetate 
and be available for further transamination with glutamate which further explains the 
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increased AST activity observed in this study. However, the data available is not sufficient to 
confirm that increase in GDH activity in the SI during diabetes is an adaptive response for 
controlling diabetic ketoacidosis. If it happens to be so, the further increase in GDH activity 
in the DO group may hence suggests further beneficial effects of OA in modulating diabetes 
induced ketoacidosis.    
4.2 Type 2 Diabetes  
As noted earlier, the synergestic effect of OA and insulin in type 1 diabetic rats has been 
reported elsewhere (Musabayane et al. 2010). Since there is residual insulin in the type 2 
diabetic model used in the study, the observed effect of OA will be in synergism with insulin. 
In the first week after induction of diabetes the weight of the diabetic animals did not change 
significantly from that of control. However, after the 2 weeks of treatment the change in body 
in diabetic animals was negligible suggesting a less severe diabetes than what was observed 
with type 1 diabetes.  
Most of the previous studies have reported SI changes in type 1 model of diabetes (Diani et 
al., 1976; Schedl and Wilson, 1971). It is confirmed here that type 2 model of diabetes also 
impart the same effect in terms of increase SI weight and length. Treatment of type 2 diabetic 
rats with both OA and metformin resulted in relatively higher SI weight/body weight as well 
as SI weight/unit length (Figure 3.7B). This effect could be attributed to the effect of both 
compounds on the absorptive and metabolic properties of the SI. Oleanolic acid has been 
reported to decreased glucose absorption and increased glycogen synthesis in an isolated SI 
from non-diabetic animals (Khathi et al., 2013). Similarly, metformin has been reported to 
decrease absorption and increase utilization of glucose by the small intestine (Bailey et al., 
1994). All of these effects could potentially induce intestine-trophic effects via adaptive 
mechanisms that can involve the incretins as well as cytokines (see discussion on type 1). 
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From Figure 3.7C, the duodenum and jejunum appear to be the main sites for the changes on 
circumferential area except for the metformin treated group which was seen to impact 
changes in all intestinal segments. 
Type 2 diabetes appeared to cause minimal changes in the villi morphology as shown in 
Figure 3.8B and Figure 3.9A-C as well as muscular stiffness (Figure 3.10) and number of 
goblet cells (Table 3.2).  This could be due to the lower hyperglycaemia in type 2 diabetic 
model compared to the other reports on type 1 diabetes. This further suggests a causative 
relationship between high blood glucose and SI morphometric changes.  
Both the specific activities of PDG and HK were not affected by type 2 diabetes suggesting 
unaltered roles of these metabolites in a less severe form of diabetes. The slight increase in 
HK activity in diabetic rats by metformin and OA treatments suggests induced increase SI 
glucose utilization. However, the decreased ALT and AST activities with same treatments 
indicate that the generated glucose-6-phosphate was not used for pyruvate generation but 
rather used for other pathways such as glycogen synthesis (Khathi et al., 2013, Bailey et al., 
1994).  
4.3 Summary 
 Blood glucose level (associated with type 1 and type 2 models), duration of diabetes and 
delay of treatment appear to play important roles in aggravating the extent of diabetes-
induced morphological changes. Type 1 diabetes (or higher blood glucose) induced more 
severe changes in terms of small intestine weight and length, villi size, underlying muscle 
thickness and goblet cells per villus than type 2 diabetes (or lower blood glucose). This was 
also true for ALT, AST and GDH activities which showed elevation due to diabetes while 
PDG was only slightly affected. The activities of ALT, AST and GDH were reversed by OA 
treatment in both studies. Both type 1 and type 2 diabetes may hence induce morphological 
72 
 
changes as well as changes in upstream enzymes of glutamine metabolism without largely 
affecting PDG. Moreover, because the small intestine is the site of absorption of orally 
delivered drugs such as OA and metformin, these drugs also induce additional morphological 
changes in the SI. This may explain the gastrointestinal disturbances associated with diabetes 
as well as oral antihyperglycaemic agents (OHAs). This study also highlights the significance 
of treating normal animals with treatment drugs as this can give significant information on 






In the early stages of diabetes, the activity of PDG slightly decreases and this is not reversed 
by OA treatment in both type 1 and type 2 diabetes model. However, OA prevents diabetes-
induced increase in the activities of upstream enzymes of glutamine metabolism while 
increasing glucose utilization by the intestine during diabetes. This may be an additional 
mechanism via which OA acts as an antihyperglycaemic agent. Furthermore, although a 
synergistic relationship exists between OA and insulin in alleviating some diabetes induced 
SI metabolic changes observed in the study, the treatments do not reverse the morphological 
changes induced in early diabetes. On the other hand, the activity of HK, ALT, AST and 
GDH where increased in the early stages of diabetes. This may be due to increased utilization 
of the product of PDG catalyzed reaction (glutamate) occurring with slight changes in PDG 
activity suggesting that existing glutaminase activity is sufficient to provide for increased 
utilization of its product.  
Further research 
1) Investigation of the quantitative aspects of the effects of OA on intestinal glutamine 
utilization.  
2) Expression studies on glutamine metabolizing enzymes investigated in this study as 
well as similar studies on other related enzymes. 
3) The mechanism through which OA induces villi changes without significantly 
affecting intestine weight and length will give insight in to the mechanism of diabetes 
(as well as other gastrointestinal diseases) induced gastrointestinal changes. 
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4) The effects of OA on long term metabolic changes induced by diabetes in the SI 
should be investigated. 
5) Effects of OA (as well as metformin) delivered parenterally will give additional 
information on the importance of SI as site of drug-stimulated glucose disposal as 
well as elucidation of the importance of SI-drug interaction in the drug-induced 
morphological changes.   
6) The gastrointestinal effects of OA should be investigated further in diabetes as the 
drug is already an oral subscription drug for liver diseases in some parts of the world 
(Sheng and Sun, 2011).  
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GLOSSARY (www.thefreedictionary.com definitions) 
Acidosis: accumulation of excess acid in the body and the lack of sufficient bicarbonate for 
effectively buffering. 
Cytokines: Chemicals made by the cells that act on other cells to stimulate or inhibit their 
function. 
Adipocytes: a fat (adipose) cell, potentially containing a large fat vacuole consisting mainly 
of triglycerides.  
Adipokines: Autocrine and paracrine factors released from human adipose tissue, in 
particular the visceral depots; including cytokines, acute phase reactants, growth factors, and 
other inflammatory mediators.  
Advanced glycation end products: proteins or lipids the become glycated after exposure to 
sugars. 
Allograft: surgical transplantation of tissue between two genetically dissimilar individuals of 
the same species, such as between two humans who are not monozygotic twins. 
Apoptosis: A natural process of self-destruction in certain cells that is determined by the 
genes and can be initiated by a stimulus or by removal of a repressor agent. 
Atherosclerosis: a general term for hardening of the blood vessels. 
Cardiovascular: pertaining to the heart and blood vessels. 
Cerebrovascular disease: general term for a brain dysfunction caused by an abnormality of 
the cerebral blood supply. 
Chylomicrons: the tiny lipoproteins of approximately 2 % protein that convey dietary fat 
throughout the body. 
Coenzyme: an organic nonprotein molecule that binds with the protein molecule to form the 
active enzyme.  
Coronary artery disease: Coronary artery disease is a narrowing or blockage of the arteries 
and vessels that provide oxygen and nutrients to the heart. 
Cosubstrate: the second or other substrate of a multisubstrate enzyme. 
Deamination: removal of the amino group, —NH2, from a compound. 
Depolarisation: to deprive of polarity by uneven ion distribution across a membrane. 
Dimer: a compound formed by combination of two identical molecules. 
Dyslipidemia: abnormality in, or abnormal amounts of, lipids and lipoproteins in the blood. 
Endothelium: the layer of epithelial cells that lines the cavities of the heart, the serous 
cavities, and the lumina of the blood and lymph vessels. 
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Exocytosis: A process of cellular secretion or excretion in which substances contained in 
vesicles are discharged from the cell by fusion of the vesicular membrane with the outer cell 
membrane. 
Gastric: pertaining to, affecting or originating in the stomach. 
Glocosuria: Excretion of glucose in the urine, especially in elevated quantities. 
Glycoconjugates: carbohydrates covalently linked with other chemical species such as 
proteins, peptides, lipids and saccharides. 
Vagal: relating to the vagus nerve (the tenth of twelve (excluding CN0) paired cranial 
nerves). 
Hormone: a chemical released by a cell, a gland, or an organ in one part of the body that 
affects cells in other parts of the organism. 
Hyperphagia: a medical sign meaning excessive hunger and abnormally large intake of 
solids by mouth. 
Hypertension: a chronic medical condition in which the blood pressure in the arteries is 
elevated. 
Hypertrophy: increase in the volume of an organ or tissue due to the enlargement of its 
component cells. 
Mesangial cells: specialized cells around blood vessels in the kidneys, at the mesangium. 
Myocardiac infarction: the medical term for an event commonly known as a heart attack. 
Nephropathy: A disease or abnormality of the kidney. 
Neuropathy: A disease or abnormality of the nervous system.  
Oxidative stress: A condition of increased oxidant production in animal cells characterized 
by the release of free radicals and resulting in cellular degeneration. 
Peripheral vascular disease: refers to the obstruction of large arteries not within the 
coronary, aortic arch vasculature, or brain. 
Postprandial: following a meal. 
Proteinuria: the presence of excessive amounts of protein in the urine. 
Retinopathy: a pathological disorder of the retina. 











































SDS-PAGE gels of the samples 
         TYPE 1                                                                              TYPE 2                                             
 
Reducing SDS-PAGE (10 %) showing protein distribution at 50 µg protein.  Mw = 
molecular weight marker. 
 
 
Western blot showing successful transfer of the 
molecular    weight marker (50 µg loading protein). 
 
 
 
